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MeCP2 is a reader of the DNA methylome that occupies a large proportion of the genome due to its high
abundance and the frequency of its target sites. It has been the subject of extensive study because of its link
with ‘MECP2-related disorders’, of which Rett syndrome is the most prevalent. This review integrates
evidence from patient mutation data with results of experimental studies using mouse models, cell lines and in
vitro systems to critically evaluate our understanding of MeCP2 protein function. Recent evidence challenges
the idea that MeCP2 is a multifunctional hub that integrates diverse processes to underpin neuronal function,
suggesting instead that its primary role is to recruit the NCoR1/2 co-repressor complex to methylated sites in
the genome, leading to dampening of gene expression.
© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Numerous chromatin-associated proteins and
noncoding RNAs work together to establish cell
type-specific epigenetic states that regulate gene
expression. These factors are vital for normal
mammalian development, with deletion of individual
members often resulting in lethality in mutant mice
[1]. Additionally, epigenetic factors often have links
to neurological disease, caused by mutations
affecting dosage such as haploinsufficiency, locus
duplications or hypomorphic alleles [2]. Here, we
discuss the role of MeCP2, a reader of the DNA
methylome, encoded by the X-linked MECP2 gene.
The gene has been implicated in several ‘MECP2-
related disorders’ [3] prompting numerous studies of
MeCP2 protein function. We discuss a spectrum of
evidence that sheds light on the molecular mechan-
isms involved, including clinical genetic investiga-
tions of genotype-phenotype correlations and
mouse models of the resulting human conditions.thor(s). Published by Elsevier Ltd. This is
ses/by-nc-nd/4.0/).Next-generation sequencing technologies have
revealed where MeCP2 binds in the genome and
how it interprets the DNA methylome to influence
gene expression. Finally, structural studies have
defined in molecular detail the interactions between
MeCP2 and its key binding partners. Together, the
findings provide a coherent picture of MeCP2
function as an essential reader of the DNA methy-
lome in the brain that optimises neuronal transcrip-
tion programmes.MECP2-Related Disorders and Mouse
Models
Loss of function mutations in the MECP2 gene in
hemizygous male patients cause neonatal encepha-
lopathy, which is usually fatal before the age of 2
years [4]. The same mutations cause the severe
neurological disorder Rett syndrome (RTT) in
heterozygous females [5]. RTT occurs in 1 in
an open access article under the CC BY-NC-ND license (http://
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1603MeCP2 function in Brain10e15,000 live female births [6], making it one of the
most common causes of monogenic intellectual
disability in females. The condition is characterised
by 6e18 months of normal development before
cognitive regression. Affected individuals lose
learned speech and purposeful hand movements,
develop stereotypies such as ‘hand-wringing’ and
acquire motor deficiencies including gait ataxia [3].
Symptoms can also include microcephaly [7],
respiratory problems [8] and seizures [9]. Disease
progression plateaus and although patients show
slow regression in later life, 70% reach the age of 50
[10]. Other MECP2 mutations that may retain more
protein function have been implicated in milder
psychiatric disorders, such as autism and schizo-
phrenia in both males and females [http://mecp2.
chw.edu.au/]. The importance of correct MeCP2
dosage is evidenced by MECP2 duplication syn-
drome, which doubles MeCP2 levels and mostly
affects males as the locus containing MECP2 is
almost always copied within the X chromosome.
This condition can run in families, with carrier
females developing no or mild symptoms because
of extreme (>90%) skewing of X chromosome
inactivation, thereby silencing the duplicated locus
[11]. Affected boys display some symptoms that
overlap with RTT including intellectual disability,
impaired language, gait abnormalities and seizures.
Individuals with this condition suffer from recurrent
infections because of immunological dysfunction,
often leading to death at around 25 years of age
[11,12]. Both RTT andMECP2 duplication syndrome
have been extensively modelled in mice, which
display overt neurological defects as well as
phenotypes that can be assessed by behavioural
testing (Table 1) [13e17]. Such studies have
established that MeCP2 is required for maintenance
of neuronal function since deletion of the gene in
adult mice causes RTT-like defects [18,19]. Excit-
ingly, reactivation ofMecp2 in symptomatic MeCP2-
deficient mice leads to phenotypic reversal, indicat-
ing that development in the absence of MeCP2
causes little or no lasting damage [20,21]. Similarly,
the behavioural phenotypes of mice overexpressing
MeCP2 can be rescued by genetic deletion or
antisense oligonucleotideemediated downregula-
tion of one copy [22]. These findings provide hope
that both disorders will be curable.MeCP2 is an Essential Reader of DNA
Methylation in the Brain
MeCP2 was initially discovered over quarter of a
century ago because of its ability to bind DNA in a
methylation-specific manner [23]. The ~90 amino
acid region responsible for binding was called the
methyl-CpG binding domain (MBD) [24]. Sequence
similarity searches using the MBD sequence identi-fied 10 other proteins that contain this domain:
MBD1-4, MBD5 (alternative names TAM1,
KIAA1461), MBD6 (alternative names TAM2,
KIAA1887), BAZ2A (alternative name TIP5),
BAZ2B, SETDB1 (alternative names ESET,
KMT1E) and SETDB2 (alternative name CLLD8)
[25e32]. Of these, only MeCP2, MBD1, MBD2 and
MBD4 have been shown to bind DNA in vitro in a
methylation-specific manner [23,26,32,33]. Specifi-
city for the same binding sites in DNA raises the
possibility of competition between these proteins,
though analysis of their temporal-spatial expression
patterns reveals differences between cell types.
MeCP2 is expressed in all tissues but reaches
near-histone abundance in neurons (~16  106
molecules per nucleus) [34]. Its levels increase
during embryonic and postnatal development, pla-
teauing at 10 years in humans [35] and 5 weeks in
mice [34]. MBD1 is expressed during neurogenesis
but is then downregulated [36]. MBD2 and MBD4 are
more widely expressed across somatic tissues, and
MBD4 is the only family member detected in
embryonic stem cells [36,37]. Whereas complete
deletion of Mecp2 in mice leads to severe neurolo-
gical symptoms and death around 9 weeks of age
[13,14], knocking out the other members results in
minimal phenotypes [36,38e43]. Even though loss of
MBD1 causes decreased neurogenesis, the animals
have a normal lifespan and only mild behavioural
defects [38,39]. These results suggest that MeCP2 is
the MBD family member with the greatest role in
interpreting the DNA methylome in the brain.
MeCP2 protein levels in human andmouse tissues
correlate poorly with transcription of the MECP2/
Mecp2 gene [35]. This may be explained by the
activity of several posttranscriptional regulatory
mechanisms, including alternative splicing, use of
different polyadenylation sites and posttranslational
modification. The gene spans four exons, which are
transcribed and spliced to form two isoforms, e1 and
e2, where only e2 includes exon 2 (Fig. 1) [44,45].
Isoform e1 is the ancestral form, conserved across
vertebrates, whereas isoform e2 is only present in
mammals. The two isoforms are very similar,
differing only at the extreme N-terminus, and most
evidence indicates that they are functionally inter-
changeable [46]. Importantly, e2 mRNA is translated
at a much lower efficiency because of the presence
of an upstream ATG [44], so the great majority of
MeCP2 protein in the brain is derived from e1. The
gene contains four alternative polyadenylation sites,
producing 30UTRs ranging from 0.1 to 8.6 kb,
although only the longest and shortest mRNAs are
detected in neurons. The use of different polyade-
nylation sites determines whether they contain
binding sites for proteins and miRNAs that regulate
mRNA stability and translation [47e49]. MeCP2
protein function and stability is also thought to be
affected by multiple posttranslational modifications,
Table 1. The RTT-like phenotypic signature in Mecp2-mutant hemizygous male mice.
Mutation (MGI) Mutation type Protein level Median survival Overt symptoms Anxiety Motor
function
Act. Gait HLC Tr. Br. GC
Null [13,95] (Mecp2tm1.1Bird) Dex3-4 None 9 wks Y þ þ þ þ þ Y/[* Y
Null [14,86,179] (Mecp2tm1.1Jae) Dex3 V. low ( internal
deletion)
6e12 wks Y þ þ þ þ þ Y Y
Null [180] (Mecp2tm1Pplt) Dex3þpart of ex4 None 8 wks Y þ þ þ þ þ Y Y
Mecp2 fl/y; Nestin-Cre [13] (Mecp2tm1Bird;
Tg(Nes-cre)1Kln)
CNS KO (Dex3-4) 65% recombination
in brain
6e12 wks Y þ þ ND ND þ ND ND
Mecp2 fl/y; Nestin-Cre [14] (Mecp2tm1Jae;
Tg(Nes-cre)1Atp)
CNS KO (Dex3) > 9 0 %
recombination
in brain
6e12 wks Y ND ND þ þ þ ND ND
Mecp2 STOP/y; Nestin-Cre [56] (Mecp2tm2Bird;
Tg(Nes-cre)1Kln)
Peripheral KO (DSTOP in
CNS)
<0.1 in periphery >1 yr (Y) e e e e e ND Y
R106W-Tavi [87] (Mecp2tm4.1Joez) RTT: MBD missense ~0.1 (of WT-TAVI) 10 wks Present, cumulative score ND ND
R111G-EGFP(tg on null background) [95] (Tg(MECP2*R111G/
EGFP)1Hzo)
RTT: MBD missense ~1 (tg) 11 wks ND ND ND ND ND ND ND ND
Y120D [88] (Mecp2tm1Nlnd) RTT: MBD missense ~0.5 14 wks þ þ þ þ ND þ NS* Y
R133C-EGFP [15] (Mecp2tm6.1Bird) RTT: MBD missense ~0 .6  ( o f WT -
EGFP)
42 wks Y þ þ þ (þ) þ Y (Y)
T158M-EGFP [15] (Mecp2tm4.1Bird) RTT: MBD missense ~0 .3  ( o f WT -
EGFP)
13 wks Y þ þ þ (þ) þ Y Y
T158M-TAVI [87] (Mecp2tm3.1Joez) RTT: MBD missense ~0.25 (of WT-
TAVI)
14 wks Present, cumulative score ND ND
T158A [86] (Mecp2tm1.1Joez) RTT: MBD missense ~0.5 16 wks Y þ þ ? þ ? Y Y
R306C [107,181] (Mecp2tm2.1Meg) RTT: NID missense ~1 ~19 wks Present, cumulative score [ Y
R306C-EGFP [15] (Mecp2tm5.1Bird) RTT: NID missense ~1 (of WT-EGFP) 30 wks Y þ þ þ þ þ Y Y
R306C-EGFP(tg on null background) [95] (Tg(MECP2*R306C/
EGFP)1Hzo)
RTT: NID missense ~1 18 wks Y ND ND ND ND ND [* Y
P225R [120] (Mecp2tm8.1Bird) RTT: ID missense ~0.22 50 wks Y þ þ þ þ þ Y Y
P322L [120] (Mecp2tm9.1Bird) RTT: CTD missense ~0.03 9 wks Y þ þ þ þ þ Y Y
R168X [182e184] (Mecp2tm1.1Jtc) RTT: ID nonsense V. low 12 wks Y þ þ þ þ þ Y Y
R255X [185] (Mecp2tm1.1Irsf) RTT: ID nonsense Undetectable 9 wks ND ND ND ND þ ND Y Y
R270X-EGFP(tg on null background)
[123] (Tg(MECP2*R270X/GFP)#Hzo)
RTT: ID nonsense ~1 (tg) 12 wks Y þ þ þ þ þ ND ND
G273X-EGFP(tg on null background)
[123] (Tg(MECP2*G273X/GFP)#Hzo)
RTT: ID nonsense ~1 (tg) 29 wks Y þ þ þ þ þ ND ND
G273X-EGFP [129] (Mecp2em5Bird) RTT: ID nonsense ~1 36 wks Y þ þ þ þ þ ND ND
S385PfsX6 [120] (Mecp2tm10.1Bird) RTT: CTD
Truncating (Patient mutation
L386HfsX5)
~ 0 . 1  ( m R N A
~0.45)
20 wks Y þ þ þ þ þ ND ND
Floxed (exons 3 þ 4) [13,18,91,92] (Mecp2tm1Bird) Hypomorphic ~0.5 >1 yr e þ (þ) e þ e NS Y
S80A [51] (Mecp2tm2.1Jae) Mutation of phosphorylation
site
~1 Normal lifespan ND ND ND ND ND ND ND Y
T308A [52] (Mecp2tm3Meg) Mutation of phosphorylation
site
~1 Normal lifespan ND ND þ ND ND ND ND Y
S421A/S424A [52] (Mecp2tm3.1Jae) Mutation of phosphorylation
sites
~1 Normal lifespan ND ND ND ND ND ND ND [
DAT-hook1 [122] (Mecp2em1Smoc) Deleted AT hook 1 ~1e1.8 >48 wks Y ND e e ND ND [ Y
G273X[DNLS]-EGFP [129] (Mecp2em6Bird) RTT ID nonsenseþmutated
NLS
~1 41 wks (NS
vs G273X-EGFP)
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1605MeCP2 function in Brainincluding neuronal activity-dependent phosphor-
ylation (Fig. 2) [50e54]. Despite the existence of
these posttranscriptional mechanisms, it is nota-
ble that cells cannot normalise MeCP2 protein
levels to cope with even a doubling in gene
dosage, as is the case in MECP2 duplication
syndrome.
The requirement for MeCP2 in different tissues
has been tested using Cre-loxP technology to
delete the gene in different cell types. Deletion of
Mecp2 in the central nervous system (CNS) using
Nestin-Cre phenocopies Mecp2-null mice, show-
ing that CNS dysfunction is the major contributor
to RTT-like pathogenicity (Table 1) [13,14]. Stu-
dies focusing on the role of MeCP2 in different
brain regions or neuronal subtypes using corre-
sponding Cre drivers demonstrate that MeCP2-
deficiency adversely affects each region or cell
type tested [55]. Conditional Mecp2 gene activa-
tion has also been used to determine the origin of
clinical features of RTT that affect peripheral
tissues. Mice with normal levels of MeCP2 in the
CNS but severely lacking MeCP2 in all peripheral
tissues are broadly healthy and do not display
RTT-like phenotypes, including gait abnormalities
and irregular breathing, demonstrating that these
traits are due to loss of MeCP2 in the brain
(Table 1) [56]. Exercise fatigue and bone fragility
are the only symptoms attributable to loss of
MeCP2 expression in the periphery. These find-
ings support the notion that the major role of
MeCP2 is to regulate neurological function.MeCP2 Binds mCG Dinucleotides and
mCAC Trinucleotides
The ability of MeCP2 to bind DNA containing
methylated mCG dinucleotides was first identified
by Southwestern assay [23] and has since been
confirmed using a variety of in vitro techniques,
including electrophoretic mobility shift assay
(EMSA), surface plasmon resonance (SPR),
fluorescence polarisation, isothermal titration
calorimetry (ITC) and 1H/15N-heteronuclear sin-
gle-quantum correlation (HSQC) nuclear magnetic
resonance spectroscopy [24,57e60]. In vivo bind-
ing has been visualised using immunohistochem-
istry or by fusion to a visible tag, taking advantage
of the high concentration of mCG sites in
pericentromeric repeats in mouse cel ls
[35,61,62], and binding dynamics were quantified
using fluorescence recovery after photobleaching
(FRAP) [63e65]. More recent studies have
focused on determining where in the mammalian
genome MeCP2 binds using chromatin immuno-
precipitation followed by next-generation sequen-
cing (ChIP-seq). This has proved to be challenging
because of both the high abundance of MeCP2
Fig. 1. Structure of theMECP2 gene and its transcripts and resulting protein isoforms. Schematic diagram of the
humanMECP2 gene comprising four exons. Above: Isoform e1mRNA is formed by splicing together exons 1, 3 and 4. The
protein is translated from exon 1. Below: Isoform e2 mRNA formed by splicing together all four exons. The protein is
translated from exon 2. Alternative polyadenylation sites could potentially be used for either isoform. The open reading
frame is shown in grey except for the different e1 and e2 N-termini (yellow and orange, respectively), the MBD (blue) and
the NID (pink). The UTRs are shown in white. The RTT-causing mutation in e1 (A2V) is annotated in red. MBD ¼ methyl-
CpG binding domain; NID ¼ NCoR1/2 interaction domain; RTT ¼ Rett syndrome.
1606 MeCP2 function in Brainprotein and the large number of potential binding
sites. In the bulk genome, CG dinucleotides occur on
average every 100 bp and are highly methylated. In
contrast, ‘CpG Islands’ are enriched in CG dinucleo-
tides and tend to be unmethylated [66e68], but they
account for only 1e2% of the genome. Consistent
with MeCP2 occupying a large fraction of mCG sites,
this analysis results in a relatively featureless ChIP-
seq signal that follows methylation density, inter-
rupted by dramatically reduced binding at unmethy-
lated CpG islands [34,69,70]. In spite of technical
limitations, peak-calling algorithms have been suc-
cessfully employed for ‘summit analysis’ using ChIP-
seq and bisulphite sequencing data from the mouse
frontal cortex to produce aggregate plots showing an
enrichment of peaks over mCG sites, but not at
unmethylated CG dinucleotides [71]. To investigatethe in vivo DNA binding footprint of MeCP2 further,
assay for transposase-accessible chromatin using
sequencing (ATAC-seq) was used to determine
protected genomic regions around mCG sites in
cultured human neurons [72]. The ATAC-seq signal
from wild-type samples was divided by the equiva-
lent signal in Mecp2 knock-out samples, revealing a
striking DNA binding footprint corresponding to the
region protected by MeCP2 over mCG [72]. This
DNA methylation-dependent footprint, which is
absent at nonmethylated CG sites, is 11 bp in size,
consistent with in vitro DNaseI footprinting [24] and
MNase protection [73].
High levels of mCH (where H is A, C or T) have
recently been discovered in the brain [74], primarily
at CA dinucleotides. The highest level of this non-CG
methylation is found at the trinucleotide CAC (~12%
Fig. 2. Posttranslational modifications of MeCP2. Schematic diagram of mouse MeCP2 protein (e2 isoform)
annotated with the activity-dependent phosphorylation sites (above) and other posttranslational modifications (below)
found in brain tissue or neuronal/glial cell lines. All activity-dependent sites are phosphorylated upon neuronal activity
except S80, which is phosphorylated under basal conditions and dephosphorylated upon neuronal activity. All residues
are conserved between human and mouse, except T441 (A443 in humans). Activity-dependent phosphorylation: S80,
S86, T148/149, S164, S229, S274, T308, S421 (human residue 423), S424 (human residue 426) [50e52,97,155e158];
Other phosphorylation: S13 [158,159], S68, S70 [157], Y120 [160], T160 [156], S166 [97,156], S178 [97], S216 [53], S399
(human residue 401) [51,158]; Ubiquitination: K12, K82, K119, K130, K135, K233, K249, K256, K271, K321 [158];
SUMOylation: K223 [161], K412 (human residue 414) [162]; Acetylation: K305/307, K321 [158], K447 (human residue
449) [163]; Methylation: R162 [164]; GlcNAcylation: T434 (human residue 436), T440/441 (human residue 442/A443)
[165]. Poly(ADP-ribosyl)-lation sites have not been mapped [166]. MBD ¼ methyl-CpG binding domain; NID ¼ NCoR1/2
interaction domain.
1607MeCP2 function in Brainof CAC sites) [70], as indicated by motif analysis of
non-CG methylation in mouse and human brain
tissue [75,76]. This is likely because of the relaxed
enzymatic specificity of the de novo DNA methyl-
transferase, DNMT3A [77]. Although the percentage
of methylation at individual CA dinucleotides is low,
the higher abundance of CA compared with CG in
the genome means that the total number of mCA
sites approaches that of mCG sites [70,74]. Inter-
estingly, non-CG methylation accumulates during
neuronal maturation at the same time as the build-up
of MeCP2 [34,35,74], raising the possibility that
MeCP2 is able to bind methylation in a non-CG
context. EMSA analysis demonstrated that MeCP2
could bind a probe containing mCH [76] and
subsequent in vitro studies narrowed the sequence
preference first to mCA [71] and then to mCAC (and
to a lesser extent mCAT) trinucleotides [70]. The
requirement for adenine in the second position
suggested that MeCP2 could recognise the methyl
group of thymine on the complementary strand.
Indeed, removal of this group by replacement of
thymine with uracil (mCAC/GTG to mCAC/GUG)
abolished the interaction [70]. Binding to mCAC and
mCAT but not mCAA or mCAG was confirmed in
cultured cells co-transfected with MeCP2 and
methylated oligonucleotides and ChIP-seq data
from mouse hypothalamus indicated a strong peak
of MeCP2 binding over mCAC (but not mCAT) sites
in vivo [70]. Binding to mCAC dramatically increases
the number of MeCP2 binding sites in the genome
and alters their distribution. Comparison between
neuronal subtypes found greater differences in the
patterns of mCH than mCG, suggesting that mCAC
is a major contributor to neuronal cell type-specific
patterns of MeCP2 binding [78,79]. In mice, these
patterns are established in the first few weeks of lifewhen DNMT3A binding and mCH deposition occurs
over the transcribed regions of lowly expressed
genes [80].
The oxidised form of methyl-cytosine, hydroxy-
methylcytosine (hmC), is the product of the first step
of the active demethylation pathway mediated by the
ten-eleven translocation (Tet) enzymes [81]. Like
mCH, hmC accumulates to uniquely high levels in
postmitotic neurons [74,82], prompting the search for
readers. In vitro analyses found that MeCP2 could
bind to probes containing hmCAC (and to a lesser
extent hmCAT) [60,70] but could not bind the
predominant form of hydroxymethyl-cytosine,
hmCG dinucleotides [57,59,70,71]. Co-transfection
of cultured cells with MeCP2 and hydroxymethylated
oligonucleotides confirmed the ability of MeCP2 to
bind hmCAC sites [70]. Unlike hmCG, hmCAC sites
are very rare in the mammalian brain [74], suggest-
ing that the ability to bind hmCAC may not be of
biological relevance. Interestingly, accumulation of
hmCG in neurons by oxidation of mCG sites means
that MeCP2 can no longer bind at these loci. This,
plus the appearance of novel mCAC binding sites,
will profoundly redistribute the profile of MeCP2
binding in the neuronal genome during postnatal
maturation.
The crystal structure of the MBD of MeCP2 bound
to a DNA molecule containing a central mCG site
showed that binding is mediated by direct interac-
tions between the nucleotides making up the mCG
site and two arginine ‘fingers’, Arg111 and Arg133
[83]. The Arg111 sidechain is constrained by
hydrogen bonding to Asp121, but Arg133 is rela-
tively unconstrained. Computational modelling
based on this structure predicted that the MBD can
bind to mCAC or hmCAC-containing DNA in a single
orientation by altering the position of Arg133 alone
1608 MeCP2 function in Brain[70]. Recent structural studies have broadly con-
firmed this hypothesis for mCAC [84]. The minor
structural change required to accommodate mCAC,
together with the likelihood that the structure of
MeCP2 outside the globular MBD is predicted to be
largely disordered [85], suggests that MeCP2 does
not interpret mCG and mCAC sites differently.DNA Binding is Essential for MeCP2
Protein Function
A functional MBD is vital for the role of MeCP2 as a
reader of the methylome. Its biological importance is
indicated by the large number of RTT-causing
missense mutations that map to this domain, almost
all of which impair binding (Table 2). Further
experimentation is needed to verify whether other,
less well-characterised mutations also impact bind-
ing. For example, RTT-causing mutations affecting
three prolines, P101, P127 and P152 were reported
to bind methylated DNA in vivo, because of their
localisation at pericentromeric foci in fixed cells [62].
However, a DNA binding defect for these mutants
cannot be ruled out as many mutants with defective
DNA binding dynamics (quantified by FRAP) never-
theless showed localisation by this assay [65]. In
addition, there is evidence that many RTT-causing
mutations in the MBD reduce protein stability as
knock-in mouse models carrying MBD mutations
have reduced protein levels (Table 1) [15,85e88].
Several other mutants, including P101S and P152R,
have been found to have reduced stability in vitro,
measured by free energy changes of protein unfold-
ing or dispersion of HSQC spectra (Table 2) [89,90].
It is likely that both disruption of DNA binding and
instability contribute to the disease phenotype in
MBD mutants, as reduced expression of the wild-
type protein to similar levels caused a much milder
phenotype (Table 1) [91,92], whereas increasing
expression of MBD mutants improved health and
survival [93,94]. The finding that transgenic mice
expressing MeCP2[R111G] at wild-type levels phe-
nocopy Mecp2-null mice proves that loss of DNA
binding alone is sufficient to cause Rett syndrome
[95]. Further underlining the importance of DNA
binding for the clinical phenotype, MeCP2[R133C]
retains more DNA binding than other MBD mutants
[15] and gives the mildest average clinical symptom
score [96].
MeCP2 protein can be posttranslationally modified
at multiple sites by phosphorylation, ubiquitination,
SUMOylation, acetylation, methylation, GlcNAcyla-
tion and poly(ADP-ribosyl)-lation (Fig. 2). The
discovery of activity-dependent phosphorylation
sites located within or close to the MBD led to the
proposal that DNA binding by MeCP2 could be
controlled by neuronal activity by addition or removal
of phosphate at these sites. Upon membranedepolarisation, Ser86, Thr148/Ser149 and
Ser164 gain phosphorylation and Ser80 loses
phosphorylation [50,51]. Biochemical analysis of
mutants that prevent or mimic phosphorylation (e.g.
S80A and S164D) suggest that phosphorylation
changes at these sites impair DNA binding [51,97].
Knock-in mice carrying the S80A mutation display
very mild RTT-like symptoms (Table 1) [51],
although it is also possible that replacement of the
highly conserved MBD residue Ser80 with alanine
directly compromises function. Computational mod-
elling based on the crystal structure predicts that
phosphorylation of Ser164 impacts DNA binding
[97]. Two activity-dependent phosphorylation sites
outside the MBD have also been proposed to impair
DNA binding: Ser421 and Ser424 (human residues
Ser423 and Ser426) [51,98], and knock-in mice with
alanine at both sites are reported to recapitulate
some of the features of mutants overexpressing
MeCP2 (Table 1) [51,98], consistent with a gain of
function effect. However, analysis of the wild-type
protein by genome-wide ChIP-seq failed to identify
any regions of the genome with reduced MeCP2
binding upon depolarisation [99]. Significantly, no
RTT missense mutations have been found at
activity-dependent phosphorylation sites. At present,
therefore, the functional role of their phosphorylation
remains elusive.The Key Interaction Partner of MeCP2 is
the NCoR1/2 Co-repressor Complex
A prevalent view of MeCP2 molecular activity is
that it is a multifunctional hub, involved in several
cellular processes via its interactions with over 40
putative binding partners (Fig. 3) [100,101]. These
roles include transcriptional repression, transcrip-
tional activation, alternative splicing, chromatin
remodelling and miRNA processing. An alternative
view, based on studies of its effects on transcription,
is that the most important role of MeCP2 is to inhibit
gene expression. DNA methylation-dependent
repression was demonstrated in early studies using
transfected reporter constructs that were enzymati-
cally modified at CG sites using a bacterial methyl-
transferase [13,102,103]. Similar experiments also
demonstrated repression mediated by mCH sites
[76]. Discovery of its repressive activity led to the
expectation that MeCP2-deficiency would cause
upregulation of a discrete set of target genes, but
the failure to unambiguously identify these in
MeCP2-deficient mice initially stymied the field.
Loss of MeCP2 instead led to small expression
changes in both directions at a large number of
genes, leading to the belief that MeCP2 might
function both to repress and activate transcription
[104,105]. To distinguish between direct and indirect
activity, recent studies have used ChIP-seq and
Table 2. RTT-causing missense mutations in the MBD affect DNA binding and/or protein stability.
RTT missense mutation mCG binding in vitro mCG binding in vivo Position in structure (PDB: 3C2I [83]) Stability Mouse model
D97Y ND Reduced [62] Interaction with R106 ND Not made
L100V Reduced [90] Partial [62,65,142] Loop Destabilised [89,90] Not made
L100R ND ND Loop ND Not made
P101R ND Binding [62,142] Loop ND Not made
P101S Binding [60] Binding [62,142] Loop Destabilised [60] Not made
P101H ND Binding [62,142,186] Loop ND Not made
P101L ND Binding [62,142] Loop ND Not made
R106W Reduced [60,90,187e189] R e d u c e d
[62,63,65,87,135,137,142,190,191]
Stabilises Asx-ST motif Destabilised [60,87] RTT-like [87]
R106Q Reduced [90] Reduced [62,192] Stabilises Asx-ST motif Destabilised [192] Not made
R106L ND ND Stabilises Asx-ST motif ND Not made
L108H ND ND Stabilises Asx-ST motif ND Not made
R111G Reduced [84,90,189] Reduced [62,65,95,137,142,186] DNA interface ND RTT-like [95]
Y120D Reduced [193] Reduced [62,88] Loop Destabilised [88] RTT-like [88]
L124F ND Reduced [62] Hydrophobic core ND Not made
P127L ND Binding [62,142] Loop ND Not made
A131D ND ND Hydrophobic core ND Not made
R133C R e d u c e d [ 1 5 , 8 4 , 9 0 , 1 8 7
e189,194]
Partial [15,65,135,137,142] DNA interface Destabilised
[15,89,194]
RTT-like [15]
R133P ND ND DNA interface ND Not made
R133L ND Reduced [62,142,186] DNA interface ND Not made
S134C Reduced [90] Binding [62,142] DNA interface Destabilised [89,90] Not made
S134F Reduced [58] ND DNA interface (Backbone) ND Not made
S134P ND ND DNA interface (Backbone) ND Not made
K135E ND Reduced [62] DNA interface (Backbone) ND Not made
L138S ND ND Alpha helix ND Not made
P152R Reduced [90] Binding [62,142,186] Loop Destabilised [89,90] Not made
F155S Reduced [90,187,188] Reduced [62,186,190] Loop Destabilised [194] Not made
D156E Reduced [90] Reduced [62] Asx-ST motif Destabilised [89,90] Not made
D156A ND ND Asx-ST motif ND Not made
F157L ND ND Asx-ST motif ND Not made
F157I ND ND Asx-ST motif ND Not made
T158M Reduced [83,90,187,188] Reduced [15,62,65,87,93,142,190] Asx-ST motif Destabilised
[15,60,87,93,194]
RTT-like [15,87,93]
T158A Reduced [83,90] Reduced [62,86,142] Asx-ST motif Destabilised [86] RTT-like [86]
G161V ND ND Asx-ST motif ND Not made










Fig. 3. MeCP2 has been reported to interact with over 40 binding partners across its length. Schematic diagram
showing the interaction sites of MeCP2 binding partners characterised by their proposed function when complexed with
MeCP2. The minimal domain required for transcriptional repression of a reporter gene (the TRD 205e310 [102]) is
indicated by the shaded red box. RTT-causing missense mutations (red) and neutral variants found in males on the ExAC
database (black) are shown above. The hotspot in the C-terminus where RTT-causing truncations occur is indicated by a
red arrow. Regions deleted in mice expressing truncated MeCP2 [130] (N¼ N-terminus, I¼ Intervening region and C¼ C-
terminus) are shown by grey dotted lines. Interaction sites for: methylated DNA 78e162 [24]; AT-rich DNA 183e195 (hook
1) [121] and 257e272 (hook 2) [121,123]; DNA (‘basic patch’) 274e340 [95]; KPNA3 249e268 [128]; KPNA4 249e270
[128]; TBL1/TBLR1 (NCoR1/2 complex) 298e309 [119]; SIN3A 108e206 and 207e308 [103,107]; c-Ski 163e309 [106];
PU.1 1e162 and 163e309 [108]; YY1 202e255 [110]; TFIIB 204e310 [117]; CBF1 [109] (unmapped); PRMT6 [109]
(unmapped); SP3 [109] (unmapped); SOX2 [111] (unmapped); BRAHMA [109] (unmapped); G9a [114] (unmapped);
HLCS [115] (unmapped); ATRX [137] 108e169; HP1a/b (unmapped), requires phospho-S229 [158]; HP1g 1e55 [131],
requires phospho-S229 [158]; SMC1/3 [167] (unmapped, requires phospho-S229 [158]); Lamin B 163e201 [168]; DNMT1
77e161, 162e206 and 207e310 [169]; TET1 [170] (unmapped); CREB1 [105] (unmapped); MYCN [171] (unmapped);
RNA 160e200 [171]; YB-1195e329 [133], requires phospho-S80 [158]; FBP11 311-CT [132]; HYPC 311-CT [132];
PRPF3 1e140 and 207e308 [172]; LEDGF 263e293 [173]; DHX9 263e269 [173]; TDP-43 [173] (unmapped); FUS [173]
(unmapped); DGCR8 380-CT, requires phospho-S80 [134]; FOXG1, requires 1e9 (unique to isoform e2) [174]; HIPK2
[155] (unmapped); CDKL5 202-CT [175]; IKKa [176] (unmapped); p300 [163] (unmapped); SIRT [163] (unmapped);
HMGB1 207-CT (motif 380e386) [134]; HTT [177] (unmapped); MBD2 163e309 [178]; MeCP2 (dimerisation) 163e309
[178]. MBD ¼ methyl-CpG binding domain; NID ¼ NCoR1/2 interaction domain; RTT ¼ Rett syndrome; SNP ¼ single
nucleotide polymorphism.
1610 MeCP2 function in Brain
1611MeCP2 function in BrainRNA-seq data to relate the level of wild-type MeCP2
binding in vivo to changes in transcription at genes in
Mecp2-nullmouse brain [69,70]. Based on the effect
of MeCP2 deficiency on expression, genes were
divided into three categories: upregulated/
unchanged/downregulated, and MeCP2-enrichment
at genes in each category was compared. Data
collected from both cerebral cortex and hypothala-
mus showed that MeCP2-enrichment was highest
over upregulated genes, consistent with the notion
that the protein normally inhibits expression directly.
Importantly, a reciprocal effect was observed in mice
over-expressing MeCP2, as downregulated genes
now had the highest MeCP2-enrichment. Lower
MeCP2-enrichment over genes that are downregu-
lated when MeCP2 is absent and upregulated when
MeCP2 is overexpressed indicates that MeCP2
does not directly activate their transcription but
suggests instead that these transcriptional changes
are an indirect consequence of altered MeCP2
levels. It is notable that gene expression changes
correlate with the density of both mCG and mCAC,
suggesting MeCP2 interprets both sites in the same
way [70e72]. The model of MeCP2 as a global
repressor fits with the high frequency of MeCP2
binding sites in the genome [70] matched by the
large number of MeCP2 molecules per cell [34] and
with the robust association between DNA methyla-
tion and transcriptional inhibition [67].
Of the large number of proposed MeCP2 interac-
tion partners, 13 proteins have been suggested to
mediate its role in transcriptional silencing. The first
group of partners comprises the HDAC-containing
NCoR1/2 [106,107] and SIN3A complexes [103]
and three co-repressors that interact with these
complexes (cSki [106], PU.1 [108] and CBF1 [109]).
The second group is made up of the transcription
factors, YY1 [110], SOX2 [111] or SP3 [112]. Third,
evidence has been presented that MeCP2 recruits
the histone methyltransferases PRMT6 [113], G9a
[114] or HLCS [115] or the chromatin remodeller
BRM [116]. Finally, MeCP2 was reported to inhibit
transcription by binding TFIIB, preventing its incor-
poration into the preinitiation complex [117]. To
date, the binding sites of only six of these (the
NCoR1/2 complex, SIN3A, c-Ski, PU.1, YY1 and
TFIIB) have been mapped to regions of MeCP2
(Fig. 3). To identify the domain required for MeCP2-
mediated transcriptional repression, fragments
were fused to the DNA binding domain of the
yeast transcription factor GAL4, and residues
207e310 were found to be sufficient to repress a
reporter gene regulated by GAL4 binding elements
[102]. This region was named the transcriptional
repression domain (TRD). As none of the mapped
interaction sites lies wholly outside the TRD,
knowledge of this domain does not intrinsically
exclude responsibility of any of the 13 interaction
partners for repression.A common approach to predicting the biological
importance of protein regions or residues relies on
evolutionary conservation. MeCP2 is 95% identical
in amino acid sequence between human andmouse.
This level of conservation is greater than the average
for all proteins (86.4% identity [118]) and therefore
suggests that the entire amino acid sequence is
functionally important. A strikingly different picture is
seen when the missense mutations causing Rett
syndrome are mapped onto the protein, as most are
confined to two discrete domains [107]: the MBD and
a second smaller cluster at the C-terminal end of the
TRD (Fig. 3). The importance of these two domains
for MeCP2 protein function is further supported by
the pattern of variants identified in the human
population, as recorded in the ExAC database.
Mapping these variants showed changes to the
protein sequence could be tolerated throughout the
protein sequence but rarely in these two domains
(Fig. 3). Interestingly, the C terminal cluster of RTT-
causing mutations coincides with the region respon-
sible for the interaction between the NCoR1/2
complex and MeCP2: residues 298e309, named
the NCoR1/2 interaction domain (NID) [107,119].
RTT-causing mutations in this cluster (P302R,
K304E, K305R and R306C) destroy this interaction
and disrupt repressive activity [107]. The NID
interacts with the WD40 domains of transducin-
beta like 1 (TBL1) and TBL1-related (TBLR1), two
paralogs that are core components of the NCoR1/2
complex. Co-crystallisation of the NID peptide with
the WD40 domain of TBLR1 showed that all four
MeCP2 residues mutated in RTT make extensive
contacts with TBLR1 [119].
The most common RTT-causing missense muta-
tion in the NID is R306C, responsible for 5% of all
cases. Knock-in mice carrying this mutation display
the same phenotypic signature as other RTT mouse
models (Table 1) [13,15,107], confirming pathogeni-
city. In addition, transcriptional analysis shows the
same patterns of dysregulation in R306C knock-in
mice as the other models [71]. Taken together, this
evidence shows that disruption of the interaction
between MeCP2 and the NCoR1/2 complex is
sufficient to cause both the neurological defects
and transcriptional changes common to all RTT
models. The presence of an activity-dependent
phosphorylation site, T308, in the NID provides a
potential mechanism by which NCoR1/2 complex
recruitment by MeCP2 could be regulated by
neuronal activity [52]. The importance of this site
was demonstrated in vivo by the production of
T308A knock-in mice. Cortical neurons derived
from T308A mice had reduced induction of activity-
dependent genes upon, consistent with retaining the
co-repressor complex. These mice displayed very
mild RTT-like symptoms including impaired motor
function, rather than the gain of function phenotype
that might be predicted (Table 1) [52].
1612 MeCP2 function in BrainTesting the Bridge Hypothesis: MeCP2
Recruits the NCoR1/2 Co-repressor
Complex to Methylated DNA
The weight of evidence discussed so far supports
a model where MeCP2 recruits the NCoR1/2 co-
repressor complex to methylated sites on chromatin,
requiring two functional domains: the MBD and the
NID. In other words, MeCP2 acts as a bridge
between DNA and the co-repressor. Although most
RTT-causing missense mutations affect these two
domains, three lie elsewhere in the protein: A2V (e1
isoform only, Fig. 1), P225R and P322L. There is
also a major cluster of truncating mutations down-
stream of the NID, making up ~10% of cases of RTT
(Fig. 3) [120]. Considering first the A2V mutation,
evidence indicates that it impairs posttranslational
processing of MeCP2. Normally, the N-terminal
methionine and up to five downstream alanine
residues are excised from newly synthesised
MeCP2, followed by acetylation of the alanine now
at the N-terminus. Replacement of the alanine in
position 2 with valine reduces the efficiency of
methionine aminopeptidase (the enzyme responsi-
ble for cleavage), leading to greatly reduced MeCP2
stability [54]. Mouse models of the two proline
mutations, P225R and P332L, reproduce the RTT
phenotype (Table 1). Both mutant proteins have
reduced abundance in the brain and both are
deficient in their ability to recruit TBL1 to pericen-
tromeric heterochromatin [120]. Two of the most
common patient mutations in the C terminal cluster
were chosen for characterisation. The first,
L386HfsX5, drastically reduced MeCP2 abundance
leading to RTT-like symptoms in knock-in mice
(equivalent mutation in mice is S385PfsX6). Patho-
genicity of the second, P389X, was not initially
recapitulated in the mouse model (equivalent muta-
tion in mice is P384_S385insPL; P387X), but
introduction of this patient mutation in the context
of the human protein sequence demonstrated that it
too leads to greatly reduced MeCP2 protein levels.
Intriguingly, the C-terminal truncating mutations are
the first RTT models found to have lower mRNA
levels, suggesting transcript stability is affected
when this region is mutated [120]. In summary, all
RTT-causing mutations adversely affect the level of
bridge function and do not therefore uncover
unanticipated functional domains in MeCP2.
A more stringent test of the bridge hypothesis is to
ask whether other characterised interaction sites in
MeCP2 that lie outside the MBD and NID are
dispensable for its function. The ExAC database
shows many single nucleotide polymorphisms
(SNPs) elsewhere in the protein indicating that
these regions can be altered without pathogenic
consequences [107]. Since mapped interaction sites
tend to be large, however, it is not obvious that theneutral SNPs could disrupt binding. Exceptions are
the two AT hooks, which have short core consensus
sequences. Indeed, the presence of destructive
SNPs in healthy hemizygous males and heterozy-
gous females suggests that the AT hooks are not
required for MeCP2 protein function [121]. Deletion
of AT hook 1 in hemizygous male knock-in mice has
no effect on lifespan but leads to mild symptoms that
may be caused by increased MeCP2 levels in some
brain regions [122]. Taken together, these findings
contradict the proposal that MeCP2 functions to
compact chromatin via the MBD and both AT hooks
[123]. The notion that MeCP2 compacts chromatin
was first raised by in vitro studies [124], but recent
analysis found that chromatin in neurons lacking
MeCP2 is in fact more compact than wild-type [125],
consistent with smaller nuclear size [126]. It is
possible that absence of MeCP2 allows access for
another compacting protein, as suggested by
increased levels of histone H1 [34], although this
hypothesis has been questioned [127]. Another
characterised short functional domain is the bipartite
nuclear localisation signal (NLS) [61] which binds to
importins, KPNA3 and KPNA4 [128,129]. Absence
of RTT mutations that inactivate the NLS suggests
that this too is nonessential [129]. In fact, disruption
of the NLS does not interfere with nuclear localisa-
tion and has no phenotypic consequences in mice
(Table 1) [128,129]. Interestingly, the small size of
MeCP2 allows it to enter the nucleus where it can be
retained by binding to methylated DNA [129].
To critically assess the functional dispensability of
large regions of MeCP2 protein outside the MBD and
NID, a series of knock-in mice expressing truncated
versions of MeCP2 were produced: DN, DNC and
DNIC (where N ¼ the region N-terminal to the MBD,
C ¼ the region C-terminal to the NID and I ¼ the
intervening region between the MBD and the NID;
Fig. 3) [130]. Both DN and DNC were expressed at
wild-type levels and hemizygous males expressing
the mutant proteins were indistinguishable from wild-
type littermates (Table 1). The dispensable N and C
termini, which together make up half of the length of
MeCP2, have been reported to contain interaction
sites for multiple binding partners including the
heterochromatin protein HP1 [131], the splicing
factors FBP11, HYPC and YB-1 [132,133], and the
miRNA processing factor DGCR8 [134] (Fig. 3).
DNIC mice were also viable, surviving for at least a
year, but displayed mild neurological defects
(Table 1) that are at least partially attributable to
the reduced protein levels in these mutants (~50% of
wild-type) [130]. This illustrates that evolutionarily
conserved regions of MeCP2 are not needed to
prevent Rett syndrome, even though they are
involved in molecular interactions. Taken together,
the evidence strongly suggests that MeCP2 exerts a
sole key function, which is to bridge methylated DNA
and the TBL1/TBLR1 subunits of the NCoR1/2
1613MeCP2 function in Braincomplex. An important corollary of this model is that
Rett syndrome is likely to be one disease with a
single root cause.
The relative dispensability of two-thirds of MeCP2
leads us to ponder why these regions are so well-
conserved throughout evolution. One theory is that
the other regions are required for higher functions that
were not detected in the phenotypic characterisation
of the mice expressing the truncated alleles [130].
Looking at variants that fall in the grey area between
no phenotypic consequence (male hemizygotes in
the ExAC database) and complete loss of function
(Rett syndrome in females and neonatal encephalo-
pathy in males) may shed light on this issue. MeCP2
mutations have been implicated in intellectual dis-
ability in males, mild intellectual disability in
females and in cognitive disorders such as autism
and schizophrenia in both males and females.
Missense mutations occur throughout the protein
[http://mecp2.chw.edu.au/] and could hypothetically
affect MeCP2 by causing subtle differences in bridge
activity or protein levels or by impacting another role
of MeCP2 that is required for higher cognitive
function. There is evidence that regions outside the
MBD contribute subtly to its interaction with DNA, as
deletions or mutations in these regions affect binding
and diffusion dynamics [63,64,121,135,136]. There is
also evidence that these regions are involved in
regulating protein stability, for example the interven-
ing domain contains Ser216 whose phosphorylation
is reported to modulate MeCP2 levels [53]. To date,
no mutations outside the MBD or NID specifically
disrupt the interaction with any other binding partner.
This has, however, been suggested for the MBD
mutation A140V, which initially did not appear to
compromise DNA binding [137]. A140V is the most
common MeCP2 mutation causing intellectual dis-
ability in boys and minor abnormalities in female
carriers [138] and its milder phenotype compared with
RTT-causing mutations is recapitulated in knock-in
mice (Table 1) [139,140]. The mutation weakens the
interaction between MeCP2 and ATRX [137], a
chromatin remodeller also mutated in cases of severe
intellectual disability [141]. However, recent reports of
minor changes in DNA binding affinity of the A140V
protein [90,142,143] indicate that more work is
needed to determine the molecular causes of
pathogenicity.
Excess NCoR1/2 Complex Recruitment
is Required for Toxicity in MECP2
duplication Syndrome
At the transcriptional level, two-fold overexpres-
sion of MeCP2 has the opposite effect compared
with loss-of-function mutations. Genes enriched for
MeCP2 binding are upregulated in Mecp2-null mice
and downregulated in mice overexpressing MeCP2[69,70]. This suggests that neurological toxicity
caused by MeCP2 overexpression is because of
excess recruitment of the NCoR1/2 co-repressor
complex at these genomic regions. If so, mutating
the NID in the additional copy/copies should alleviate
the toxic effects. This possibility has been addressed
using two independent mouse models of MeCP2
overexpression: (1) a PAC transgene containing the
entire human locus [16] and (2) expression of mouse
Mecp2 isoform e2 from the Mapt locus fused to the
first 31 amino acids of Tau [17]. The former, which
express MeCP2 at two-fold wild-type levels, dis-
played neurological phenotypes in behavioural tests
and developed late-onset overt symptoms with 30%
mortality between 5 months and 1 year of age [16].
Introduction of R306C into the transgene abolished
these phenotypic consequences [95]. This result
was confirmed using the second model with a more
extreme phenotype. Mice with 3.8-fold levels of wild-
type MeCP2 failed to survive to weaning, but this
was fully rescued by the introduction of the R306C
mutation into Tau-MeCP2. Not only did the mice
survive to adulthood, they remained healthy with no
phenotype in behavioural tests (Table 1) [94]. Thus,
a functional NID is essential to confer the toxicity
caused by MeCP2 overexpression.Breaking the Bridge by Mutating TBLR1
can Occasionally Cause Rett Syndrome
The Bridge hypothesis implies that mutations in
the NCoR1/2 complex might also break the DNA-
MeCP2-NCoR1/2 complex bridge, resulting in RTT.
The core NCoR1/2 complex is 1e2 MDa in size and
contains NCoR1, NCoR2, GPS2, HDAC3, TBL1 and
TBLR1 subunits. Knockout mice lacking the genes
encoding core subunits (except TBL1) have been
produced and show that each is essential for
embryonic development [144e148]. As the NCoR1/
2 complex has other molecular functions including,
for example, repression via nuclear receptors in the
steroid/thyroid/retinoid superfamily, it is unsurprising
that loss-of-function mutations in its components
have a more severe phenotype than loss of MeCP2.
To specifically abolish its role in MeCP2-mediated
repression, its interaction surface would need to be
mutated so that MeCP2 can no longer bind without
affecting other interactions. The NCoR1/2 complex
consists of a central TBL1/TBLR1 tetramer, with
each TBL1/TBLR1 dimer bound to one molecule of
NCoR1 or NCoR2. These in turn act as scaffolds for
GPS2 and HDAC3 [149]. TBL1/TBLR1 tetramerisa-
tion involves their N-terminal domains, with their C-
terminal WD40 domains located on the outside of
this complex, suggesting the MeCP2 interaction
surface can be specifically mutated. A key difference
between mutating this interface within MeCP2 and





















































































































































































































































































































































































































































































































































































































































































































































1614 MeCP2 function in BrainTBLR1 paralogs can bind MeCP2, and disrupting
mutations are unlikely to occur in both genes.
Another consideration is that patients with Rett
syndrome are mosaics due to X chromosome
inactivation, with half their cells expressing the
wild-type and half the mutant copy of the X-linked
MECP2 gene. The location of the gene encoding
TBL1, TBL1X, on the X chromosome raised the
possibility that mutations in this gene could have
similar molecular consequences. However, the
conditions for this scenario are not met as TBL1X
is thought to be biallelically expressed [150] and
TBL1 is not the major paralog in the braindTBLR1 is
in fact five times more abundant [151].
Analysis of disease-causing mutations in the TBL
genes and their corresponding clinical outcome may
illuminate the role of the NCoR1/2 complex in the
brain. The DECIPHER database lists cases of
developmental delay in both males and females
caused by deletions and duplications in the genes
encoding TBL1 and TBLR1, suggesting that TBL
protein dosage impacts development. Furthermore,
as is common for genes that escape X chromosome
inactivation, dosage inmales ismaintained inhumans
and other primates by a Y-linked homolog, TBL1Y,
and duplication of this gene also causes develop-
mental delay [152, DECIPHER]. The DECIPHER
database and case reports list numerous missense
mutations in TBLR1 that cause developmental delay
in heterozygotes. These are mostly located in the
WD40 domain (Table 3), suggesting some may
impact MeCP2 binding. Intriguingly, two patient
mutations, D369E and P444R, were recently shown
to abolish the bridge between TBLR1 and MeCP2,
whilst retaining the ability of TBLR1 to pulldown
HDAC3 (indicating that the complex remains intact)
[119]. The challenge now is to compare the clinical
characteristics of patients with TBLR1WD40 domain
mutations with RTT patients. Indeed, one patient with
the D370N mutation was diagnosed with classical
RTT, meeting all main and six out of 11 supporting
criteria [153]. The Y446C mutation, which causes
Pierpont syndrome, on the other hand is clinically
distinct fromRTT as patients lack the essential period
of apparently normal development followed by
regression [153,154]. It is therefore likely that loss of
MeCP2 binding plays a role in the pathogenicity of
some but not all of these mutations.Concluding Remarks
There is now strong evidence that MeCP2 is an
important reader of the DNA methylome in neurons.
Loss-of-function mutations in MECP2 that cause
Rett syndrome in patients pinpoint the MBD
(responsible for binding to methylated DNA) and
the NID (responsible for binding to the NCoR1/2 co-
repressor complex) as the key domains essential for
1615MeCP2 function in BrainMeCP2 protein function. Analysis of the co-crystal
structures of these interactions shows in atomic
detail how the mutated residues contribute to binding
to these macromolecules, and most mutations have
been demonstrated experimentally to impair binding.
The bridge model, which proposes that MeCP2
recruits the NCoR1/2 complex to methylated DNA, is
supported by the observation that all RTT-causing
mutations throughout the length of MeCP2 affect this
function, and deletion of the regions outside these
two domains has only mild phenotypic conse-
quences. These findings significantly enhance our
understanding of the underlying biology of MECP2-
related disorders and link these molecular mechan-
isms to disease-causing mutations in TBLR1. After
many years of research, recent findings now convey
a coherent model for the role of MeCP2 in globally
modulating gene expression, particularly in neurons.
While there is evidently more to learn about the
downstream metabolic consequences of MeCP2
dysfunction, the new knowledge promises to under-
pin efforts to devise therapies for RTT and other
MECP2-related disorders.Acknowledgements
The authors thank Jacky Guy, Jim Selfridge,
Matthew Lyst and John Connelly for comments on
the manuscript. R.T. is a Sir Henry Wellcome
Postdoctoral Fellow (210913/Z/18/Z). A.B. is sup-
ported by a Wellcome Trust Centre grant (091580/Z/
10/Z), a Wellcome Investigator Award (107930/Z/15/
Z), a Rett Syndrome Research Trust Consortium
grant, a European Research Council Advanced
grant (EC 694295 Gen-Epix) and is a member of
the Simons Initiative for the Developing Brain. The
University of Edinburgh is a charitable body,
registered in Scotland, with registration number
SC005336.Conflicts of Interest
None.
Received 3 September 2019;
Received in revised form 4 October 2019;
Accepted 5 October 2019







[1] T.F. Meehan, N. Conte, D.B.West, J.O. Jacobsen, J. Mason,
J. Warren, C.K. Chen, I. Tudose, M. Relac, P. Matthews,
N. Karp, L. Santos, T. Fiegel, N. Ring, H. Westerberg,
S. Greenaway, D. Sneddon, H. Morgan, G.F. Codner,
M.E. Stewart, J. Brown, N. Horner, M. Haendel,
N. Washington, C.J. Mungall, C.L. Reynolds, J. Gallegos,
V. Gailus-Durner, T. Sorg, G. Pavlovic, L.R. Bower,
M. Moore, I. Morse, X. Gao, G.P. Tocchini-Valentini,
Y. Obata, S.Y. Cho, J.K. Seong, J. Seavitt, A.L. Beaudet,
M.E. Dickinson, Y. Herault, W. Wurst, M.H. De Angelis,
K.C. Kent Lloyd, A.M. Flenniken, L.M.J. Nutter,
S. Newbigging, C. McKerlie, M.J. Justice, S.A. Murray,
K.L. Svenson, R.E. Braun, J.K. White, A. Bradley, P. Flicek,
S. Wells, W.C. Skarnes, D.J. Adams, H. Parkinson,
A.M. Mallon, S.D.M. Brown, D. Smedley, Disease model
discovery from 3,328 gene knockouts by the international
mouse phenotyping Consortium, Nat. Genet. 49 (2017)
1231e1238, https://doi.org/10.1038/ng.3901.
[2] The Deciphering Developmental Disorders Study, Large-
scale discovery of novel genetic causes of developmental
disorders, Nature 519 (2015) 223e228, https://doi.org/
10.1038/nature14135.
[3] J.L. Neul, W.E. Kaufmann, D.G. Glaze, J. Christodoulou,
A.J. Clarke, N. Bahi-Buisson, H. Leonard, M.E.S. Bailey,
N.C. Schanen, M. Zappella, A. Renieri, P. Huppke,
A.K. Percy, Rett syndrome: revised diagnostic criteria and
nomenclature, Ann, Neurol. Now. 68 (2010) 944e950,
https://doi.org/10.1002/ana.22124.
[4] P. Kankirawatana, H. Leonard, C. Ellaway, J. Scurlock,
A. Mansour, C.M. Makris, L.S. Dure IV, M. Friez, J. Lane,
C. Kiraly-Borri, V. Fabian, M. Davis, J. Jackson,
J. Christodoulou, W.E. Kaufmann, D. Ravine, A.K. Percy,
Early progressive encephalopathy in boys and MECP2
mutations, Neurology 67 (2006) 164e166, https://doi.org/
10.1212/01.wnl.0000223318.28938.45.
[5] R.E. Amir, I.B. Van den Veyver, M. Wan, C.Q. Tran,
U. Francke, H.Y. Zoghbi, Rett syndrome is caused by
mutations in X-linked MECP2, encoding methyl-CpG-bind-
ing protein 2, Nat. Genet. 23 (1999) 185e188, https://
doi.org/10.1038/13810.
[6] B. Hagberg, Rett's Syndrome: prevalence and impact on
progressive severe mental retardation in girls, Acta Pae-
diatr. Scand. 74 (1985) 405e408, https://doi.org/10.1111/
j.1651-2227.1985.tb10993.x.
[7] A.M. Kerr, J.B.P. Stephenson, Clinical topics Rett's syn-
drome in the west of Scotland, Br. Med. J. 291 (1985)
579e582, https://doi.org/10.1136/bmj.291.6495.579.
[8] A.K. Percy, J.L. Neul, D.G. Glaze, K.J. Motil, S.A. Skinner,
M. Omar Khwaja, H.-S. Lee, J.B. Lane, J.O. Barrish,
F. Annese, L. McNair, J. Graham, K. Barnes, Rett syndrome
diagnostic criteria: lessons from the natural history study,
Ann. Neurol. 68 (2010) 951e955, https://doi.org/10.1016/
j.freeradbiomed.2008.10.025. The.
[9] B. Hagberg, J. Aicardi, K. Dias, O. Ramos, A progressive
syndrome of autism, dementia, ataxia, and loss of
purposeful hand use in girls: Rett's syndrome: report of 35
cases, Ann. Neurol. 14 (1983) 471e479, https://doi.org/
10.1097/00001577-198901020-00018.
[10] D.C. Tarquinio, W. Hou, J.L. Neul, W.E. Kaufmann,
D.G. Glaze, K.J. Motil, S.A. Skinner, H.S. Lee,
1616 MeCP2 function in BrainA.K. Percy, The changing face of survival in Rett syndrome
and MECP2-related disorders, Pediatr. Neurol. 53 (2015)
402e411, ht tps: / /do i .org/10.1016/ j .pediat rneur-
ol.2015.06.003.
[11] H. Van Esch, MECP2 duplication syndrome, Mol. Syndro-
mol. 2 (2011) 128e136, https://doi.org/10.1159/000329580.
[12] H. Van Esch, M. Bauters, J. Ignatius, M. Jansen,
M. Raynaud, K. Hollanders, D. Lugtenberg, T. Bienvenu,
L.R. Jensen, J. Ge, C. Moraine, P. Marynen, J. Fryns,
G. Froyen, Duplication of the MECP2 region is a frequent
cause of severe mental retardation and progressive
neurological symptoms in males, Am. J. Hum. Genet. 77
(2005) 442e453, https://doi.org/10.1086/444549.
[13] J. Guy, B. Hendrich, M. Holmes, J.E. Martin, A. Bird,
A mouse Mecp2-null mutation causes neurological symp-
toms that mimic Rett syndrome, Nat. Genet. 27 (2001)
322e326, https://doi.org/10.1038/85899.
[14] R.Z. Chen, S. Akbarian, M. Tudor, R. Jaenisch, Deficiency
of methyl-CpG binding protein-2 in CNS neurons results in
a Rett-like phenotype in mice, Nat. Genet. 27 (2001)
327e331, https://doi.org/10.1038/85906.
[15] K. Brown, J. Selfridge, S. Lagger, J. Connelly, D. De Sousa,
S. Webb, J. Guy, C. Merusi, M. V Koerner, A. Bird, The
molecular basis of variable phenotypic severity among
common missense mutations causing Rett syndrome, Hum.
Mol. Genet. 25 (2016) 558e570, https://doi.org/10.1093/
hmg/ddv496.
[16] A.L. Collins, J.M. Levenson, A.P. Vilaythong, R. Richman,
D.L. Armstrong, J.L. Noebels, J.D. Sweatt, H.Y. Zoghbi,
Mild overexpression of MeCP2 causes a progressive
neurological disorder in mice, Hum. Mol. Genet. 13 (2004)
2679e2689, https://doi.org/10.1093/hmg/ddh282.
[17] S. Luikenhuis, E. Giacometti, C.F. Beard, R. Jaenisch,
Expression of MeCP2 in postmitotic neurons rescues Rett
syndrome in mice, Proc. Natl. Acad. Sci. U. S. A. 101 (2004)
6033e6038, https://doi.org/10.1073/pnas.0401626101.
[18] H. Cheval, J. Guy, C. Merusi, D. De Sousa, J. Selfridge,
A. Bird, Postnatal inactivation reveals enhanced requirement
for MeCP2 at distinct age windows, Hum. Mol. Genet. 21
(2012) 3806e3814, https://doi.org/10.1093/hmg/dds208.
[19] C.M. McGraw, R.C. Samaco, H.Y. Zoghbi, Adult neural
function requires MeCP2, Science 333 (2011) 186, https://
doi.org/10.1126/science.1206593.
[20] J. Guy, J. Gan, J. Selfridge, S. Cobb, A. Bird, Reversal of
neurological defects in a mouse model of Rett syndrome,
Science 315 (2007) 1143e1147, https://doi.org/10.1126/
science.1138389.
[21] L. Robinson, J. Guy, L. McKay, E. Brockett, R.C. Spike,
J. Selfridge, D. De Sousa, C. Merusi, G. Riedel, A. Bird,
S.R. Cobb, Morphological and functional reversal of pheno-
types in a mouse model of Rett syndrome, Brain 135 (2012)
2699e2710, https://doi.org/10.1093/brain/aws096.
[22] Y. Sztainberg, H. Chen, J.W. Swann, S. Hao, B. Tang,
Z. Wu, J. Tang, Y.-W. Wan, Z. Liu, F. Rigo, H.Y. Zoghbi,
Reversal of phenotypes in MECP2 duplication mice using
genetic rescue or antisense oligonucleotides, Nature 528
(2015) 123e126, https://doi.org/10.1038/nature16159.
[23] J.D. Lewis, R.R. Meehan, W.J. Henzel, I. Maurer-Fogy,
P. Jeppesen, F. Klein, A. Bird, Purification, sequence, and
cellular localization of a novel chromosomal protein that
binds to methylated DNA, Cell 69 (1992) 905e914, https://
doi.org/10.1016/0092-8674(92)90610-o.
[24] X. Nan, R.R. Meehan, A. Bird, Dissection of the methyl-
CpG binding domain from the chromosomal proteinMeCP2, Nucleic Acids Res. 21 (1993) 4886e4892,
https://doi.org/10.1093/nar/21.21.4886.
[25] S.H. Cross, R.R. Meehan, X. Nan, A. Bird, A component of
the transcriptional repressor MeCP1 shares a motif with
DNA methyltransferase and HRX proteins, Nat. Genet. 16
(1997) 256e259, https://doi.org/10.1038/nm0798-822.
[26] B. Hendrich, A. Bird, Identification and characterization of a
family of mammalian methyl-CpG binding proteins, Mol.
Cell. Biol. 18 (1998) 6538e6547, https://doi.org/10.1128/
MCB.18.11.6538.
[27] R. Strohner, A. Nemeth, P. Jansa, U. Hofmann-Rohrer,
R. Santoro, G. L€angst, I. Grummt, NoRC - a novel member
of mammalian ISWI-containing chromatin remodeling ma-
chines, EMBO J. 20 (2001) 4892e4900, https://doi.org/
10.1093/emboj/20.17.4892.
[28] H. Mabuchi, H. Fujii, G. Calin, H. Mabuchi, H. Fujii, G. Calin,
H. Alder, M. Negrini, L. Rassenti, T.J. Kipps, F. Bullrich,
C.M. Croce, Novel candidate genes for leukemogenesis at
chromosome 13q14 , a region commonly deleted in B-cell
chronic lymphocytic leukemia deleted in B-cell chronic
lymphocytic leukemia 1, Cancer Res. 61 (2001) 2870e2877.
[29] D.C. Schultz, K. Ayyanathan, D. Negorev, G.G. Maul,
F.J. Rauscher Iii, SETDB1: a novel KAP - 1 - associated
histone H3 , lysine 9 - specific methyltransferase that
contributes to HP1 - mediated silencing of euchromatic
genes by KRAB zinc - finger proteins, Genes Dev. 16
(2002) 919e932, https://doi.org/10.1101/gad.973302.
[30] T.C. Roloff, H.H. Ropers, U.A. Nuber, Comparative study of
methyl-CpG-binding domain proteins, BMC Genomics 4
(2003) 1, https://doi.org/10.1186/1471-2164-4-1.
[31] B. Hendrich, S. Tweedie, The methyl-CpG binding domain
and the evolving role of DNA methylation in animals,
Trends Genet. 19 (2003) 269e277, https://doi.org/10.1016/
S0168-9525(03)00080-5.
[32] Q. Du, P.-L. Luu, C. Stirzaker, S.J. Clark, Methyl-CpG-binding
domain proteins: readers of the epigenome, Epigenomics 7
(2015) 1051e1073, https://doi.org/10.2217/epi.15.39.
[33] S. Laget, M. Joulie, F. Le Masson, N. Sasai, E. Christians,
S. Pradhan, R.J. Roberts, P.A. Defossez, The human
proteins MBD5 and MBD6 associate with heterochromatin
but they do not bind methylated DNA, PLoS One 5 (2010),
e11982, https://doi.org/10.1371/journal.pone.0011982.
[34] P.J. Skene, R.S. Illingworth, S. Webb, A. Kerr, K.D. James,
D.J. Turner, R. Andrews, A.P. Bird, Neuronal MeCP2 is
expressed at near histone-octamer levels and globally
alters the chromatin state, Mol. Cell 37 (2010) 457e468,
https://doi.org/10.1016/j.molcel.2010.01.030.Neuronal.
[35] M.D. Shahbazian, B. Antalffy, D.L. Armstrong, H.Y. Zoghbi,
Insight into Rett syndrome: MeCP2 levels display tissue-
and cell-specific differences and correlate with neuronal
maturation, Hum. Mol. Genet. 11 (2002) 115e124, https://
doi.org/10.1093/hmg/11.2.115.
[36] K.H. Wood, B.S. Johnson, S.A. Welsh, J.Y. Lee, Y. Cui,
E. Krizman, E.S. Brodkin, J.A. Blendy, M.B. Robinson,
M.S. Bartolomei, Z. Zhou, Tagging methyl-CpG-binding
domain proteins reveals different spatiotemporal expres-
sion and supports distinct functions, Epigenomics 8 (2016)
455e473, https://doi.org/10.2217/epi-2015-0004.
[37] B. Hendrich, U. Hardeland, H.H. Ng, J. Jiricny, a Bird, The
thymine glycosylase MBD4 can bind to the product of
deamination at methylated CpG sites, Nature 401 (1999)
301e304, https://doi.org/10.1038/35006691.
[38] X. Zhao, T. Ueba, B.R. Christie, B. Barkho, M.J. McConnell,
K. Nakashima, E.S. Lein, B.D. Eadie, A.R. Willhoite,
1617MeCP2 function in BrainA.R. Muotri, R.G. Summers, J. Chun, K.-F. Lee, F.H. Gage,
Mice lacking methyl-CpG binding protein 1 have deficits in
adult neurogenesis and hippocampal function, Proc. Natl.
Acad. Sci. U. S. A. 100 (2003) 6777e6782, https://doi.org/
10.1073/pnas.1131928100.
[39] A.M. Allan, X. Liang, Y. Luo, C. Pak, X. Li, K.E. Szulwach,
D. Chen, P. Jin, X. Zhao, The loss of methyl-CpG binding
protein 1 leads to autism-like behavioral deficits, Hum. Mol.
Genet. 17 (2008) 2047e2057, https://doi.org/10.1093/hmg/
ddn102.
[40] B. Hendrich, J. Guy, B. Ramsahoye, V. a Wilson, A. Bird,
Closely related proteins MBD2 and MBD3 play distinctive
but interacting roles in mouse development, Genes Dev. 15
(2001) 710e723, https://doi.org/10.1101/gad.194101.
[41] O.J. Sansom, J. Berger, S.M. Bishop, B. Hendrich, A. Bird,
A.R. Clarke, Deficiency of Mbd2 suppresses intestinal
tumorigenesis, Nat. Genet. 34 (2003) 145e147, https://
doi.org/10.1038/ng1155.
[42] C.B. Millar, J. Guy, O.J. Sansom, J. Selfridge,
E. MacDougall, B. Hendrich, P.D. Keightley, S.M. Bishop,
A.R. Clarke, A. Bird, Enhanced CpG mutability and
tumorigenesis in MBD4-deficient mice, Science 297
(2002) 403e405, https://doi.org/10.1126/science.1073354.
[43] E. Wong, K. Yang, M. Kuraguchi, U. Werling, E. Avdievich,
K. Fan, M. Fazzari, B. Jin, A.M.C. Brown, M. Lipkin,
W. Edelmann, Mbd4 inactivation increases Cright-arrowT
transition mutations and promotes gastrointestinal tumor
formation, Proc. Natl. Acad. Sci. U. S. A. 99 (2002)
14937e14942, https://doi.org/10.1073/pnas.232579299.
[44] S. Kriaucionis, A. Bird, The major form of MeCP2 has a
novel N-terminus generated by alternative splicing, Nucleic
Acids Res. 32 (2004) 1818e1823, https://doi.org/10.1093/
nar/gkh349.
[45] G.N. Mnatzakanian, H. Lohi, I. Munteanu, S.E. Alfred,
T. Yamada, P.J.M. MacLeod, J.R. Jones, S.W. Scherer,
N.C. Schanen, M.J. Friez, J.B. Vincent, B. a Minassian,
A previously unidentifiedMECP2 open reading frame defines
a new protein isoform relevant to Rett syndrome, Nat. Genet.
36 (2004) 339e341, https://doi.org/10.1038/ng1327.
[46] B. Kerr, J. Soto C, M. Saez, A. Abrams, K. Walz, J.I. Young,
Transgenic complementation of MeCP2 deficiency: pheno-
typic rescue of Mecp2-null mice by isoform-specific
transgenes, Eur. J. Hum. Genet. 20 (2012) 69e76, https://
doi.org/10.1038/ejhg.2011.145.
[47] M.E. Klein, D.T. Lioy, L. Ma, S. Impey, G. Mandel,
R.H. Goodman, Homeostatic regulation of MeCP2 expres-
sion by a CREB-induced microRNA, Nat. Neurosci. 10
(2007) 1513e1514, https://doi.org/10.1038/nn2010.
[48] V.A. Gennarino, C.E. Alcott, C. Chen, A. Chaudhury,
M.A. Gillentine, J.A. Rosenfeld, S. Parikh, J.W. Wheless,
E.R. Roeder, D.D.G. Horovitz, E.K. Roney, J.L. Smith,
S.W. Cheung, W. Li, J.R. Neilson, C.P. Schaaf, NUDT21
-spanning CNVs lead to neuropsychiatric disease and
altered MeCP2 abundance via alternative polyadenylation,
Elife 4 (2015), e10782, https://doi.org/10.7554/eLife.10782.
[49] D.C. Rodrigues, D.S. Kim, G. Yang, K. Zaslavsky,
K.C.H. Ha, R.S.F. Mok, P.J. Ross, M. Zhao, A. Piekna,
W. Wei, B.J. Blencowe, Q. Morris, J. Ellis, MECP2 is post-
transcriptionally regulated during human neurodevelop-
ment by combinatorial action of RNA-binding proteins and
miRNAs, Cell Rep. 17 (2016) 720e734, https://doi.org/
10.1016/j.celrep.2016.09.049.
[50] Z. Zhou, E.J. Hong, S. Cohen, W. ning Zhao, H. yi H. Ho,
L. Schmidt, W.G. Chen, Y. Lin, E. Savner, E.C. Griffith,L. Hu, J.A.J. Steen, C.J. Weitz, M.E. Greenberg, Brain-
specific phosphorylation of MeCP2 regulates activity-
dependent Bdnf transcription, dendritic growth, and spine
maturation, Neuron 52 (2006) 255e269, https://doi.org/
10.1016/j.neuron.2006.09.037.
[51] J. Tao, K. Hu, Q. Chang, H. Wu, N.E. Sherman,
K. Martinowich, R.J. Klose, C. Schanen, R. Jaenisch,
W. Wang, Y.E. Sun, Phosphorylation of MeCP2 at Serine
80 regulates its chromatin association and neurological
function, Proc. Natl. Acad. Sci. U. S. A. 106 (2009)
4882e4887, https://doi.org/10.1073/pnas.0811648106.
[52] D.H. Ebert, H.W. Gabel, N.D. Robinson, N.R. Kastan,
L.S. Hu, S. Cohen, A.J. Navarro, M.J. Lyst, R. Ekiert,
A.P. Bird, M.E. Greenberg, Activity-dependent phosphor-
ylation of MeCP2 threonine 308 regulates interaction with
NCoR, Nature 499 (2013) 341e345, https://doi.org/
10.1038/nature12348.
[53] L.M. Lombardi, M. Zaghlula, Y. Sztainberg, S.A. Baker,
T.J. Klisch, A.A. Tang, E.J. Huang, H.Y. Zoghbi, An RNA
interference screen identifies druggable regulators of
MeCP2 stability, Sci. Transl. Med. 9 (2017), eaaf7588,
https://doi.org/10.1126/scitranslmed.aaf7588.
[54] T.I. Sheikh, A. Martínez de Paz, S. Akhtar, J. Ausio,
J.B. Vincent, MeCP2 isoform N-terminal modifications
affect its degradation rate and are disrupted by the Ala2Val
Rett mutation, Hum. Mol. Genet. 26 (2017) 4132e4141,
https://doi.org/10.1093/hmg/ddx300.
[55] J. Guy, H. Cheval, J. Selfridge, A. Bird, The role of MeCP2
in the brain, Annu. Rev. Cell Dev. Biol. 27 (2011) 631e652,
https://doi.org/10.1146/annurev-cellbio-092910-154121.
[56] P.D. Ross, J. Guy, J. Selfridge, B. Kamal, E. Tanner,
T.H. Gil l ingwater, R.A. Jones, C.M. Loughrey,
C.S. Mccarroll, M.E.S.B. Adrian, S. Cobb, Exclusive
expression of MeCP2 in the nervous system distinguishes
between brain and peripheral Rett syndrome-like pheno-
types, Hum. Mol. Genet. 25 (2016) 4389e4404, https://
doi.org/10.1093/hmg/ddw269.
[57] V. Valinluck, H.-H. Tsai, D.K. Rogstad, A. Burdzy, A. Bird,
L.C. Sowers, Oxidative damage to methyl-CpG sequences
inhibits the binding of the methyl-CpG binding domain
(MBD) of methyl-CpG binding protein 2 (MeCP2), Nucleic
Acids Res. 32 (2004) 4100e4108, https://doi.org/10.1093/
nar/gkh739.
[58] M. Mellen, P. Ayata, S. Dewell, S. Kriaucionis, N. Heintz,
MeCP2 binds to 5hmC enriched within active genes and
accessible chromatin in the nervous system, Cell 151
(2012 ) 1417e14130 , h t t ps : / / do i . o rg / 10 .1016 /
j.cell.2012.11.022.
[59] H. Hashimoto, Y. Liu, A.K. Upadhyay, Y. Chang,
S.B. Howerton, P.M. Vertino, X. Zhang, X. Cheng, Recogni-
tion and potential mechanisms for replication and erasure of
cytosine hydroxymethylation, Nucleic Acids Res. 40 (2012)
4841e4849, https://doi.org/10.1093/nar/gks155.
[60] M.J. Sperlazza, S.M. Bilinovich, L.M. Sinanan, F.R. Javier,
D.C. Williams, Structural basis of MeCP2 distribution on
non-CpG methylated and hydroxymethylated DNA, J. Mol.
Biol. 429 (2017) 1581e1594, https://doi.org/10.1016/
j.jmb.2017.04.009.
[61] X. Nan, P. Tate, E. Li, A. Bird, DNA methylation specifies
chromosomal localization of MeCP2, Mol. Cell. Biol. 16
(1996) 414e421, https://doi.org/10.1128/mcb.16.1.414.
[62] S. Kudo, Y. Nomura, M. Segawa, N. Fujita, M. Nakao,
C. Schanen, M. Tamura, Heterogeneity in residual function
of MeCP2 carrying missense mutations in the methyl CpG
1618 MeCP2 function in Brainbinding domain, J. Med. Genet. 40 (2003) 487e493, https://
doi.org/10.1136/jmg.40.7.487.
[63] M. Marchi, A. Guarda, A. Bergo, N. Landsberger,
C. Kilstrup-Nielsen, G.M. Ratto, M. Costa, Spatio-temporal
dynamics and localization of MeCP2 and pathological
mutants in living cells, Epigenetics 2 (2007) 187e197,
https://doi.org/10.4161/epi.2.3.5057.
[64] A. Kumar, S. Kamboj, B.M. Malone, S. Kudo, J.L. Twiss,
K.J. Czymmek, J.M. LaSalle, N.C. Schanen, Analysis of
protein domains and Rett syndrome mutations indicate that
multiple regions influence chromatin-binding dynamics of the
chromatin-associated protein MECP2 in vivo, J. Cell Sci. 121
(2008) 1128e1137, https://doi.org/10.1242/jcs.016865.
[65] L. Schmiedeberg, P. Skene, A. Deaton, A. Bird, A temporal
threshold for formaldehyde crosslinking and fixation, PLoS
One 4 (2009), e4636, https://doi.org/10.1371/journal.-
pone.0004636.
[66] A. Bird, M. Taggart, M. Frommer, O.J. Miller, D. Macleod,
A fraction of the mouse genome that is derived from islands
of nonmethylated, CpG-rich DNA, Cell 40 (1985) 91e99,
https://doi.org/10.1016/0092-8674(85)90312-5.
[67] A. Bird, DNA methylation patterns and epigenetic memory,
Genes Dev. 16 (2002) 6e21, https://doi.org/10.1101/
gad.947102.
[68] A. Deaton, A. Bird, CpG islands and the regulation of
transcription, Genes Dev. 25 (2011) 1010e1022, https://
doi.org/10.1101/gad.2037511.1010.
[69] B. Kinde, D.Y. Wu, M.E. Greenberg, H.W. Gabel, DNA
methylation in the gene body influences MeCP2-mediated
gene repression, Proc. Natl. Acad. Sci. U. S. A. 113 (2016)
15114e15119, https://doi.org/10.1073/pnas.1618737114.
[70] S. Lagger, J.C. Connelly, G. Schweikert, S. Webb,
J. Selfr idge, B.H. Ramsahoye, M. Yu, C. He,
G. Sanguinetti, L.C. Sowers, M.D. Walkinshaw, A. Bird,
MeCP2 recognizes cytosine methylated tri-nucleotide and
di-nucleotide sequences to tune transcription in the
mammalian brain, PLoS Genet. 13 (2017), e1006793,
https://doi.org/10.1371/journal.pgen.1006793.
[71] H.W. Gabel, B. Kinde, H. Stroud, C.S. Gilbert, D.a. Harmin,
N.R. Kastan, M. Hemberg, D.H. Ebert, M.E. Greenberg,
Disruption of DNA-methylation-dependent long gene re-
pression in Rett syndrome, Nature 522 (2015) 89e93,
https://doi.org/10.1038/nature14319.
[72] J. Cholewa-waclaw, R. Shah, S. Webb, K. Chhatbar,
B. Ramsahoye, O. Pusch, Quantitative modelling predicts
the impact of DNA methylation on RNA polymerase II
traffic, Proc. Natl. Acad. Sci. U. S. A. 116 (2019)
14995e15000, https://doi.org/10.1073/pnas.1903549116.
[73] T. Nikitina, R.P. Ghosh, R.a. Horowitz-Scherer,
J.C. Hansen, S.a. Grigoryev, C.L. Woodcock, MeCP2-
Chromatin interactions include the formation of chromato-
some-like structures and are altered in mutations causing
Rett syndrome, J. Biol. Chem. 282 (2007) 28237e28245,
https://doi.org/10.1074/jbc.M704304200.
[74] R. Lister, E. a Mukamel, J.R. Nery, M. Urich, C. a Puddifoot,
N.D. Johnson, J. Lucero, Y. Huang, A.J. Dwork,
M.D. Schultz, M. Yu, J. Tonti-Filippini, H. Heyn, S. Hu,
J.C. Wu, A. Rao, M. Esteller, C. He, F.G. Haghighi,
T.J. Sejnowski, M.M. Behrens, J.R. Ecker, Global epige-
nomic reconfiguration during mammalian brain develop-
ment, Science 341 (2013) 1237905, https://doi.org/
10.1126/science.1237905.
[75] K.E. Varley, J. Gertz, K.M. Bowling, S.L. Parker,
T.E. Reddy, F. Pauli-behn, M.K. Cross, B. a Williams, J.a Stamatoyannopoulos, G.E. Crawford, D.M. Absher,
B.J. Wold, R.M. Myers, Dynamic DNA methylation across
diverse human cell lines and tissues Dynamic DNA
methylation across diverse human cell lines and tissues,
Genome Res. 23 (2013) 555e567, https://doi.org/10.1101/
gr.147942.112.
[76] J.U. Guo, Y. Su, J.H. Shin, J. Shin, H. Li, B. Xie, C. Zhong,
S. Hu, T. Le, G. Fan, H. Zhu, Q. Chang, Y. Gao, G.-L. Ming,
H. Song, Distribution, recognition and regulation of non-
CpG methylation in the adult mammalian brain, Nat.
Neurosci. 17 (2014) 215e222, https://doi.org/10.1038/
nn.3607.
[77] B.H. Ramsahoye, D. Biniszkiewicz, F. Lyko, V. Clark, a
P. Bird, R. Jaenisch, Non-CpG methylation is prevalent in
embryonic stem cells and may be mediated by DNA
methyltransferase 3a. Proc. Natl. Acad. Sci. U. S. A. 97
( 2000 ) 5237e5242 , h t t p s : / / d o i . o r g / 1 0 . 1 073 /
pnas.97.10.5237.
[78] A. Mo, E.A. Mukamel, F.P. Davis, C. Luo, G.L. Henry,
S. Picard, M.A. Urich, J.R. Nery, T.J. Sejnowski, R. Lister,
S.R. Eddy, J.R. Ecker, J. Nathans, Epigenomic signatures
of neuronal diversity in the mammalian brain, Neuron 86
(2015) 1369e1384, https://doi.org/10.1016/j.neu-
ron.2015.05.018.
[79] W. Renthal, L.D. Boxer, S. Hrvatin, E. Li, A. Silberfeld,
M.A. Nagy, E.C. Griffith, T. Vierbuchen, M.E. Greenberg,
Characterization of human mosaic Rett syndrome brain
tissue by single-nucleus RNA sequencing, Nat. Neurosci.
21 (2018), https://doi.org/10.1038/s41593-018-0270-6.
[80] H. Stroud, S.C. Su, S. Hrvatin, A.W. Greben, W. Renthal,
L.D. Boxer, M.A. Nagy, D.R. Hochbaum, B. Kinde,
H.W. Gabel, M.E. Greenberg, Early-life gene expression
in neurons modulates lasting epigenetic states, Cell 171
( 2017 ) 1151e1164 , h t t p s : / / d o i . o r g / 1 0 . 1 016 /
j.cell.2017.09.047, e16.
[81] D. Globisch, M. Münzel, M. Müller, S. Michalakis,
M. Wagner, S. Koch, T. Brückl, M. Biel, T. Carell, Tissue
distribution of 5-hydroxymethylcytosine and search for
active demethylation intermediates, PLoS One 5 (2010),
e15367, https://doi.org/10.1371/journal.pone.0015367.
[82] S. Kriaucionis, N. Heintz, The nuclear DNA base 5-
hydroxymethylcytosine is present in Purkinje neurons and
the brain, Science 325 (2014) 929e930, https://doi.org/
10.1126/science.1169786.
[83] K.L. Ho, I.W. McNae, L. Schmiedeberg, R.J. Klose,
A.P. Bird, M.D. Walkinshaw, MeCP2 binding to DNA
depends upon hydration at methyl-CpG, Mol. Cell 29
(2008) 525e531, ht tps: / /do i .org/10.1016/ j .mol -
cel.2007.12.028.
[84] M. Lei, W. Tempel, K. Liu, J. Min, Plasticity at the DNA
recognition site of the MeCP2 mCG-binding domain,
Biochim. Biophys. Acta - Gene Regul. Mech. 1862 (2019)
194409, https://doi.org/10.1016/j.bbagrm.2019.194409.
[85] R.P. Ghosh, T. Nikitina, R.A. Horowitz-scherer,
L.M. Gierasch, V.N. Uversky, K. Hite, J.C. Hansen,
L. Christopher, Unique physical properties and interactions
of the domains of methylated DNA binding protein 2
(MeCP2), Biochemistry 49 (2010) 4395e4410, https://
doi.org/10.1021/bi9019753.
[86] D. Goffin, M. Allen, L. Zhang, M. Amorim, I.-T.J. Wang, A.-
R.S. Reyes, A. Mercado-Berton, C. Ong, S. Cohen, L. Hu,
J. a Blendy, G.C. Carlson, S.J. Siegel, M.E. Greenberg,
Z. Zhou, Rett syndrome mutation MeCP2 T158A disrupts
DNA binding, protein stability and ERP responses, Nat.
1619MeCP2 function in BrainNeurosci. 15 (2012) 274e283, https://doi.org/10.1038/
nn.2997.
[87] B.S. Johnson, Y.T. Zhao, M. Fasolino, J.M. Lamonica,
Y.J. Kim, G. Georgakilas, K.H. Wood, D. Bu, Y. Cui,
D. Goffin, G. Vahedi, T.H. Kim, Z. Zhou, Biotin tagging of
MeCP2 in mice reveals contextual insights into the Rett
syndrome transcriptome, Nat. Med. 23 (2017) 1203e1214,
https://doi.org/10.1038/nm.4406.
[88] A. Gandaglia, E. Brivio, S. Carli, M. Palmieri, F. Bedogni,
G. Stefanelli, A. Bergo, B. Leva, C. Cattaneo,
L. Pizzamiglio, M. Cicerone, V. Bianchi, C. Kilstrup-Nielsen,
I. D'Annessa, D. Di Marino, P. D'Adamo, F. Antonucci,
A. Frasca, N. Landsberger, A novel Mecp2Y120D knock-in
model displays similar behavioral traits but distinct mole-
cular features compared to the Mecp2-null mouse implying
precision medicine for the treatment of Rett syndrome, Mol.
Neurobiol. 56 (2018) 4838e4854, https://doi.org/10.1007/
s12035-018-1412-2.
[89] T. Kucukkal, Y. Yang, O. Uvarov, W. Cao, E. Alexov,
Impact of Rett syndrome mutations on MeCP2 MBD
stability, Biochemistry 54 (2015) 6357e6368, https://
doi.org/10.1021/acs.biochem.5b00790.
[90] Y. Yang, T.G. Kucukkal, J. Li, E. Alexov, W. Cao, Binding
analysis of methyl-CpG binding domain of MeCP2 and Rett
syndrome mutations, ACS Chem. Biol. 11 (2016)
2706e2715, https://doi.org/10.1021/acschembio.6b00450.
[91] B. Kerr, M. Alvarez-Saavedra, M. a Saez, A. Saona,
J.I. Young, Defective body-weight regulation, motor control
and abnormal social interactions in Mecp2 hypomorphic
mice, Hum. Mol. Genet. 17 (2008) 1707e1717, https://
doi.org/10.1093/hmg/ddn061.
[92] R.C. Samaco, J.D. Fryer, J. Ren, S. Fyffe, H.T. Chao,
Y. Sun, J.J. Greer, H.Y. Zoghbi, J.L. Neul, A partial loss of
function allele of Methyl-CpG-binding protein 2 predicts a
human neurodevelopmental syndrome, Hum. Mol. Genet.
17 (2008) 1718e1727, https://doi.org/10.1093/hmg/
ddn062.
[93] J.M. Lamonica, D.Y. Kwon, D. Goffin, P. Fenik,
B.S. Johnson, Y. Cui, H. Guo, S. Veasey, Z. Zhou,
Elevating expression of MeCP2 T158M rescues DNA
binding and Rett syndrome-like phenotypes, J. Clin.
Investig. 127 (2017) 1889e1904, https://doi.org/10.1172/
JCI90967.
[94] M. V Koerner, L. Fitzpatrick, J. Selfridge, J. Guy, D. De
Sousa, R. Tillotson, A. Kerr, Z. Sun, M.A. Lazar, M.J. Lyst,
A. Bird, Toxicity of overexpressed MeCP2 is independent of
HDAC3 activity, Genes Dev. 32 (2018) 1514e1524, https://
doi.org/10.1101/gad.320325.118.
[95] L.D. Heckman, M.H. Chahrour, H.Y. Zoghbi, Rett-causing
mutations reveal two domains critical for MeCP2 function
and for toxicity in MECP2 duplication syndrome mice, Elife
(2014), eLife2014, https://doi.org/10.7554/eLife.02676.001
e02676.
[96] V.A. Cuddapah, R.B. Pillai, K.V. Shekar, J.B. Lane,
K.J. Motil, S.A. Skinner, D.C. Tarquinio, D.G. Glaze,
G. McGwin, W.E. Kaufmann, A.K. Percy, J.L. Neul,
M.L. Olsen, Methyl-CpG-binding protein 2 (MECP2) muta-
tion type is associated with disease severity in Rett
syndrome, J. Med. Genet. 51 (2014) 152e158, https://
doi.org/10.1136/jmedgenet-2013-102113.
[97] G. Stefanelli, A. Gandaglia, M. Costa, M.S. Cheema, D. Di
Marino, I. Barbiero, C. Kilstrup-Nielsen, J. Ausio,
N. Landsberger, Brain phosphorylation of MeCP2 at serine
164 is developmentally regulated and globally alters itschromatin association, Sci. Rep. 6 (2016) 28295, https://
doi.org/10.1038/srep28295.
[98] H. Li, X. Zhong, K.F. Chau, E.C. Williams, Q. Chang, Loss
of activity-induced phosphorylation of MeCP2 enhances
synaptogenesis, LTP and spatial memory, Nat. Neurosci.
14 (2011) 1001e1008, https://doi.org/10.1038/nn.2866.
[99] S. Cohen, H.W. Gabel, M. Hemberg, A.N. Hutchinson,
L.A. Sadacca, D.H. Ebert, D.A. Harmin, R.S. Greenberg,
V.K. Verdine, Z. Zhou, W.C. Wetsel, A.E. West,
M.E. Greenberg, Genome-wide activity-dependent MeCP2
phosphorylation regulates nervous system development
and function, Neuron 72 (2011) 72e85, https://doi.org/
10.1016/j.neuron.2011.08.022.
[100] F. Della Ragione, M. Vacca, S. Fioriniello, G. Pepe,
M.D. Esposito, MECP2 , a multi-talented modulator of
chromatin architecture, Brief. Funct. Genom. 15 (2016)
420e431, https://doi.org/10.1093/bfgp/elw023.
[101] M.J. Lyst, A. Bird, Rett syndrome: a complex disorder with
simple roots, Nat. Rev. Genet. 16 (2015) 261e274, https://
doi.org/10.1038/nrg3897.
[102] X. Nan, F.J. Campoy, A. Bird, MeCP2 is a transcriptional
repressor with abundant binding sites in genomic chroma-
tin, Cell 88 (1997) 471e481, https://doi.org/10.1016/S0092-
8674(00)81887-5.
[103] X. Nan, H.H. Ng, C.A. Johnson, C.D. Laherty, B.M. Turner,
R.N. Eisenman, A. Bird, Transcriptional repression by the
methyl-CpG-binding protein MeCP2 involves a histone
deacetylase complex, Nature 393 (1998) 386e389, https://
doi.org/10.1038/30764.
[104] M. Tudor, S. Akbarian, R.Z. Chen, R. Jaenisch, Nonlinear
partial differential equations and applications: transcrip-
tional profiling of a mouse model for Rett syndrome reveals
subtle transcriptional changes in the brain, Proc. Natl.
Acad. Sci. U. S. A. 99 (2002) 15536e15541, https://doi.org/
10.1073/pnas.242566899.
[105] M. Chahrour, S.Y. Jung, C. Shaw, X. Zhou, S.T.C. Wong,
J. Qin, H.Y. Zoghbi, MeCP2, a key contributor to
neurological disease, activates and represses transcription,
Science 320 (2008) 1224e1229, https://doi.org/10.1126/
science.1153252.
[106] K. Kokura, S.C. Kaul, R. Wadhwa, T. Nomura, M.M. Khan,
T. Shinagawa, T. Yasukawa, C. Colmenares, S. Ishii, The
Ski protein family is required for MeCP2-mediated tran-
scriptional repression, J. Biol. Chem. 276 (2001)
34115e34121, https://doi.org/10.1074/jbc.M105747200.
[107] M.J. Lyst, R. Ekiert, D.H. Ebert, C. Merusi, J. Nowak,
J. Selfridge, J. Guy, N.R. Kastan, N.D. Robinson, F. de
Lima Alves, J. Rappsilber, M.E. Greenberg, A. Bird, Rett
syndrome mutations abolish the interaction of MeCP2 with
the NCoR/SMRT co-repressor, Nat. Neurosci. 16 (2013)
898e902, https://doi.org/10.1038/nn.3434.
[108] M. Suzuki, T. Yamada, F. Kihara-Negishi, T. Sakurai,
T. Oikawa, Direct association between PU.1 and MeCP2
that recruits mSin3A-HDAC complex for PU.1-mediated
transcriptional repression, Oncogene 22 (2003)
8688e8698, https://doi.org/10.1038/sj.onc.1207182.
[109] J. Mann, F. Oakley, F. Akiboye, a Elsharkawy, a
W. Thorne, D. a Mann, Regulation of myofibroblast
transdifferentiation by DNA methylation and MeCP2:
implications for wound healing and fibrogenesis, Cell
Death Differ. 14 (2007) 275e285, https://doi.org/10.1038/
sj.cdd.4401979.
[110] G. Forlani, E. Giarda, U. Ala, F. Di Cunto, M. Salani,
R. Tupler, C. Kilstrup-Nielsen, N. Landsberger, The
1620 MeCP2 function in BrainMeCP2/YY1 interaction regulates ANT1 expression at
4q35: novel hints for Rett syndrome pathogenesis, Hum.
Mol. Genet. 19 (2010) 3114e3123, https://doi.org/10.1093/
hmg/ddq214.
[111] K.E. Szulwach, X. Li, R.D. Smrt, Y. Li, Y. Luo, L. Lin,
N.J. Santistevan, W. Li, X. Zhao, P. Jin, Cross talk between
microRNA and epigenetic regulation in adult neurogenesis,
J. Cell Biol. 189 (2010) 127e141, https://doi.org/10.1083/
jcb.200908151.
[112] C.K. Hwang, C.S. Kim, D.K. Kim, P. Law, L. Wei, H.H. Loh,
Up-regulation of the mu-opioid receptor gene is mediated
through chromatin remodeling and transcriptional factors in
differentiated neuronal cells, Mol. Pharmacol. 78 (2010)
58e68, https://doi.org/10.1124/mol.110.064311.
[113] S. Dhawan, S. Georgia, S. ing Tschen, G. Fan,
A. Bhushan, Pancreatic beta cell identity is maintained
by DNA methylation-mediated repression of Arx, Dev. Cell
20 (2011) 419e429, https://doi.org/10.1016/j.dev-
cel.2011.03.012.
[114] S. Subbanna, N.N. Nagre, M. Shivakumar, N.S. Umapathy,
D. Psychoyos, B.S. Basavarajappa, Ethanol induced
acetylation of histone at G9a exon1 and G9a-mediated
histone H3 dimethylation leads to neurodegeneration in
neonatal mice, Neuroscience 258 (2014) 422e432, https://
doi.org/10.1016/j.neuroscience.2013.11.043.
[115] J. Xue, S.S.K. Wijeratne, J. Zempleni, Holocarboxylase
synthetase synergizes with methyl CpG binding protein 2
and DNA methyltransferase 1 in the transcriptional repres-
sion of long-terminal repeats, Epigenetics 8 (2013)
504e511, https://doi.org/10.4161/epi.24449.
[116] K.N. Harikrishnan, M.Z. Chow, E.K. Baker, S. Pal,
S. Bassal, D. Brasacchio, L. Wang, J.M. Craig,
P.L. Jones, S. Sif, A. El-Osta, Brahma links the SWI/SNF
chromatin-remodeling complex with MeCP2-dependent
transcriptional silencing, Nat. Genet. 37 (2005) 254e264,
https://doi.org/10.1038/ng1516.
[117] N.K. Kaludov, A.P. Wolffe, MeCP2 driven transcriptional
repression in vitro: selectivity for methylated DNA, action at
a distance and contacts with the basal transcription
machinery, Nucleic Acids Res. 28 (2000) 1921e1928,
https://doi.org/10.1093/nar/28.9.1921.
[118] W. Makałowski, Mark S. Boguski, Evolutionary parameters
of the transcribed mammalian genome : an analysis of
2,820 orthologous rodent and human sequences, Proc.
Natl. Acad. Sci. U. S. A. 95 (1998) 9407e9412, https://
doi.org/10.1073/pnas.95.16.9407.
[119] V. Kruusvee, M.J. Lyst, C. Taylor, Z. Tarnauskait _e,
A.P. Bird, A.G. Cook, Structure of the MeCP2eTBLR1
complex reveals a molecular basis for Rett syndrome and
related disorders, Proc. Natl. Acad. Sci. U. S. A. 114 (2017)
E3243eE3250, https://doi.org/10.1073/pnas.1700731114.
[120] J. Guy, B. Alexander-Howden, L. Fitzpatrick, D. Desousa,
M. V Koerner, J. Selfridge, A. Bird, A mutation-led search for
novel functional domains in MeCP2, Hum. Mol. Genet. 27
(2018) 2531e2545, https://doi.org/10.1093/hmg/ddy159.
[121] M.J. Lyst, J. Connelly, C. Merusi, A. Bird, Sequence-
specific DNA binding by AT-hook motifs in MeCP2, FEBS
Lett. 590 (2016) 2927e2933, https://doi.org/10.1002/1873-
3468.12328.
[122] M. Xu, P. Song, W. Huang, R. He, Y. He, X. Zhou, Y. Gu,
Disruption of AT-hook 1 domain in MeCP2 protein caused
behavioral abnormality in mice, Biochim. Biophys. Acta
(BBA) - Mol. Basis Dis. 1864 (2018) 347e358, https://
doi.org/10.1016/j.bbadis.2017.10.022.[123] S.A. Baker, L. Chen, A.D. Wilkins, P. Yu, O. Lichtarge,
H.Y. Zoghbi, An AT-hook domain in MeCP2 determines the
clinical course of Rett syndrome and related disorders, Cell
152 (2013) 984e996, h t tps : / /do i .o rg /10.1016/
j.cell.2013.01.038.
[124] P.T. Georgel, R.A. Horowitz-Scherer, N. Adkins,
C.L. Woodcock, P.A. Wade, J.C. Hansen, Chromatin
compaction by human MeCP2. Assembly of novel
secondary chromatin structures in the absence of DNA
methylation, J. Biol. Chem. 278 (2003) 32181e32188,
https://doi.org/10.1074/jbc.M305308200.
[125] M.W. Linhoff, S.K. Garg, G. Mandel, A high-resolution
imaging approach to investigate chromatin architecture in
complex tissues, Cell 163 (2015) 246e255, https://doi.org/
10.1016/j.cell.2015.09.002.
[126] M. Yazdani, R. Deogracias, J. Guy, R.A. Poot, A. Bird,
Y. Barde, Disease modeling using embryonic stem cells:
MeCP2 regulates nuclear size and RNA synthesis in
neurons, Stem Cells 30 (2012) 2128e2139, https://
doi.org/10.1002/June.
[127] A. Ito-Ishida, H.K. Yamalanchili, Y. Shao, S.A. Baker,
L.D. Heckman, L.A. Lavery, J. Kim, L.M. Lombardi, Y. Sun,
Z. Liu, H.Y. Zoghbi, Genome-wide distribution of linker
histone H1.0 is independent of MeCP2, Nat. Neurosci. 21
(2018) 794e798, https://doi.org/10.1038/s41593-018-
0155-8.
[128] S.A. Baker, L.M. Lombardi, H.Y. Zoghbi, Karyopherin alpha
3 and karyopherin alpha 4 mediate nuclear import of
methyl-CpG binding protein 2, J. Biol. Chem. 290 (2015)
22485e22493, https://doi.org/10.1074/jbc.M115.658104.
[129] M.J. Lyst, R. Ekiert, J. Guy, J. Selfridge, M.V. Koerner,
C. Merusi, D. De Sousa, A. Bird, Affinity for DNA
contributes to NLS independent nuclear localization of
MeCP2, Cell Rep. 24 (2018) 2213e2220, https://doi.org/
10.1016/j.celrep.2018.07.099.
[130] R. Tillotson, J. Selfridge, M.V. Koerner, K.K.E. Gadalla,
J. Guy, D. De Sousa, R.D. Hector, S.R. Cobb, A. Bird,
Radically truncated MeCP2 reverses Rett syndrome-like
neurological defects, Nature 550 (2017) 398e401, https://
doi.org/10.1038/nature24058.
[131] N. Agarwal, T. Hardt, A. Brero, D. Nowak, U. Rothbauer,
A. Becker, H. Leonhardt, M.C. Cardoso, MeCP2 interacts
with HP1 and modulates its heterochromatin association
during myogenic differentiation, Nucleic Acids Res. 35
(2007) 5402e5408, https://doi.org/10.1093/nar/gkm599.
[132] J.P. Buschdorf, W.H. Str€atling, A WW domain binding
region in methyl-CpG-binding protein MeCP2: impact on
Rett syndrome, J. Mol. Med. 82 (2004) 135e143, https://
doi.org/10.1007/s00109-003-0497-9.
[133] J.I. Young, E.P. Hong, J.C. Castle, J. Crespo-Barreto,
A.B. Bowman, M.F. Rose, D. Kang, R. Richman,
J.M. Johnson, S. Berget, H.Y. Zoghbi, Regulation of RNA
splicing by the methylation-dependent transcriptional re-
pressor methyl-CpG binding protein 2, Proc. Natl. Acad.
Sci. U. S. A. 102 (2005) 17551e17558, https://doi.org/
10.1073/pnas.0507856102.
[134] T.-L. Cheng, Z. Wang, Q. Liao, Y. Zhu, W.-H. Zhou, W. Xu,
Z. Qiu, MeCP2 suppresses nuclear microRNA processing
and dendritic growth by regulating the DGCR8/Drosha
complex, Dev. Cell 28 (2014) 547e560, https://doi.org/
10.1016/j.devcel.2014.01.032.
[135] F.M. Piccolo, Z. Liu, P. Dong, C.-L. Hsu, E.I. Stoyanova,
A. Rao, R. Tjian, N. Heintz, Mecp2 nuclear dynamics in live
neurons results from low and high affinity chromatin
1621MeCP2 function in Braininteractions, BioRxiv (2019), https://doi.org/10.2139/
ssrn.3376659.
[136] T.I. Sheikh, R. Harripaul, M. Ayub, J.B. Vincent, MeCP2
AT-Hook1 mutations in patients with intellectual disability
and/or schizophrenia disrupt DNA binding and chromatin
compaction in vitro, Hum. Mutat. 39 (2018) 717e728,
https://doi.org/10.1002/humu.23409.
[137] X. Nan, J. Hou, A. Maclean, J. Nasir, M.J. Lafuente, X. Shu,
S. Kriaucionis, A. Bird, Interaction between chromatin
proteins MECP2 and ATRX is disrupted by mutations that
cause inherited mental retardation, Proc. Natl. Acad. Sci. U.
S. A. 104 (2007) 2709e2714, https://doi.org/10.1073/
pnas.0608056104.
[138] J.L. Neul, The relationship of Rett syndrome and MECP2
disorders to autism, Transl. Res. 14 (2012) 253e262.
[139] G.M. Jentarra, S.L. Olfers, S.G. Rice, N. Srivastava,
G.E. Homanics, M. Blue, S. Naidu, V. Narayanan, Abnorm-
alities of cell packing density and dendritic complexity in the
MeCP2 A140V mouse model of Rett syndrome/X-linked
mental retardation, BMC Neurosci. 11 (2010), https://
doi.org/10.1186/1471-2202-11-19.
[140] L.Y. Ma, C. Wu, Y. Jin, M. Gao, G.H. Li, D. Turner,
J.X. Shen, S.J. Zhang, V. Narayanan, G. Jentarra, J. Wu,
Electrophysiological phenotypes of MeCP2 A140V mutant
mouse model, CNS Neurosci. Ther. 20 (2014) 420e428,
https://doi.org/10.1111/cns.12229.
[141] R.J. Gibbons, D.J. Picketts, L. Villard, D.R. Higgs, Muta-
tions in a putative global transcriptional regulator cause X-
linked mental retardation with a-thalassemia (ATR-X
syndrome), Cell 80 (1995) 837e845, https://doi.org/
10.1016/0092-8674(95)90287-2.
[142] N. Agarwal, A. Becker, K.L. Jost, S. Haase, B.K. Thakur,
A. Brero, T. Hardt, S. Kudo, H. Leonhardt, M.C. Cardoso,
MeCP2 Rett mutations affect large scale chromatin
organization, Hum. Mol. Genet. 20 (2011) 4187e4195,
https://doi.org/10.1093/hmg/ddr346.
[143] J.Y. Chia, W.S. Tan, C.L. Ng, N. Hu, H.L. Foo, A/T run
geometry of B-form DNA is independent of bound methyl-
CpG binding domain , cytosine methylation and flanking
sequence, Sci. Rep. 6 (2016) 31212, https://doi.org/
10.1038/srep31210.
[144] K. Jepsen, O. Hermanson, T.M. Onami, A.S. Gleiberman,
V. Lunyak, R.J. Mcevilly, R. Kurokawa, V. Kumar, F. Liu,
E. Seto, S.M. Hedrick, G. Mandel, C.K. Glass, D.W. Rose,
M.G. Rosenfeld, S. Brook, N. York, Combinatorial roles of
the nuclear receptor corepressor in transcription and
development, Cell 102 (2000) 753e763, https://doi.org/
10.1016/s0092-8674(00)00064-7.
[145] K. Jepsen, D. Solum, T. Zhou, R.J. McEvilly, H.J. Kim,
C.K. Glass, O. Hermanson, M.G. Rosenfeld, SMRT-
mediated repression of an H3K27 demethylase in progres-
sion from neural stem cell to neuron, Nature 450 (2007)
415e419, https://doi.org/10.1038/nature06270.
[146] S. Bhaskara, B.J. Chyla, J.M. Amann, S.K. Knutson,
D. Cortez, Z. Sun, S.W. Hiebert, Article deletion of histone
deacetylase 3 reveals critical roles in S phase progression
and DNA damage control, Mol. Cell 30 (2008) 61e72,
https://doi.org/10.1016/j.molcel.2008.02.030.
[147] C. Guo, Y. Li, C. Gow, M. Wong, J. Zha, C. Yan, H. Liu,
Y. Wang, T.P. Burris, J. Zhang, The optimal corepressor
function of nuclear receptor corepressor (NCoR) for
peroxisome proliferator-activated receptor g requires G
protein pathway suppressor 2, J. Biol. Chem. 290 (2015)
3666e3679, https://doi.org/10.1074/jbc.M114.598797.[148] M.E. Dickinson, A.M. Flenniken, X. Ji, L. Teboul,
M.D. Wong, J.K. White, T.F. Meehan, W.J. Weninger,
H. Westerberg, H. Adissu, C.N. Baker, L. Bower,
J.M. Brown, L. Brianna Caddle, F. Chiani, D. Clary,
J. Cleak, M.J. Daly, J.M. Denegre, B. Doe, M.E. Dolan,
S.M. Edie, H. Fuchs, V. Gailus-Durner, A. Galli,
A. Gambadoro, J. Gallegos, S. Guo, N.R. Horner, C. wei
Hsu, S.J. Johnson, S. Kalaga, L.C. Keith, L. Lanoue,
T.N. Lawson, M. Lek, M. Mark, S. Marschall, J. Mason,
M.L. McElwee, S. Newbigging, L.M.J. Nutter,
K.A. Peterson, R. Ramirez-Solis, D.J. Rowland, E. Ryder,
K.E. Samocha, J.R. Seavitt, M. Selloum, Z. Szoke-Kovacs,
M. Tamura, A.G. Trainor, I. Tudose, S. Wakana, J. Warren,
O. Wendling, D.B. West, L. Wong, A. Yoshiki,
D.G. MacArthur, G.P. Tocchini-Valentini, X. Gao,
P. Flicek, A. Bradley, W.C. Skarnes, M.J. Justice,
H.E. Parkinson, M. Moore, S. Wells, R.E. Braun,
K.L. Svenson, M. Hrabe de Angelis, Y. Herault,
T. Mohun, A.M. Mal lon, R. Mark Henkelman,
S.D.M. Brown, D.J. Adams, K.C. Kent Lloyd, C. McKerlie,
A.L. Beaudet, M. Bucan, S.A. Murray, M. McKay, B. Urban,
C. Lund, E. Froeter, T. LaCasse, A. Mehalow, E. Gordon,
L.R. Donahue, R. Taft, P. Kutney, S. Dion, L. Goodwin,
S. Kales, R. Urban, K. Palmer, F. Pertuy, D. Bitz, B. Weber,
P. Goetz-Reiner, H. Jacobs, E. Le Marchand, A. El Amri,
L. El Fertak, H. Ennah, D. Ali-Hadji, A. Ayadi,
M. Wattenhofer-Donze, S. Jacquot, P. Andre,
M.C. Birling, G. Pavlovic, T. Sorg, I. Morse, F. Benso,
M.E. Stewart, C. Copley, J. Harrison, S. Joynson, R. Guo,
D. Qu, S. Spring, L. Yu, J. Ellegood, L. Morikawa,
X. Shang, P. Feugas, A. Creighton, P.C. Penton,
O. Danisment, N. Griggs, C.L. Tudor, A.L. Green,
C. Icoresi Mazzeo, E. Siragher, C. Lillistone, E. Tuck,
D. Gleeson, D. Sethi, T. Bayzetinova, J. Burvill, B. Habib,
L. Weavers, R. Maswood, E. Miklejewska, M. Woods,
E. Grau, S. Newman, C. Sinclair, E. Brown, S. Ayabe,
M. Iwama, A. Murakami, High-throughput discovery of
novel developmental phenotypes, Nature 537 (2016)
508e514, https://doi.org/10.1038/nature19356.
[149] J. Oberoi, L. Fairall, P.J. Watson, J.-C. Yang,
Z . Cz imme re r , T . Kampmann , B .T . Gou l t ,
J.A. Greenwood, J.T. Gooch, B.C. Kallenberger,
L. Nagy, D. Neuhaus, J.W.R. Schwabe, Structural basis
for the assembly of the SMRT/NCoR core transcriptional
repression machinery, Nat. Struct. Mol. Biol. 18 (2011)
177e184, https://doi.org/10.1038/nsmb.1983.
[150] M.T. Bassi, R.S. Ramesar, B. Caciotti, I.M. Winship, A. De
Grandi, M. Riboni, P.L. Townes, P. Beighton, A. Ballabio,
G. Borsani, X-linked late-onset sensorineural deafness
caused by a deletion involving OA1 and a novel gene
containing WD-40 repeats, Am. J. Hum. Genet. 64 (1999)
1604e1616, https://doi.org/10.1086/302408.
[151] C.G. Spruijt, F. Gnerlich, A.H. Smits, T. Pfaffeneder,
P.W.T.C. Jansen, C. Bauer, M. Münzel, M. Wagner,
M. Müller, F. Khan, H.C. Eberl, A. Mensinga,
A.B. Brinkman, K. Lephikov, U. Müller, J. Walter,
R. Boelens, H. Van Ingen, H. Leonhardt, T. Carell,
M. Vermeulen, Dynamic readers for 5-(Hydroxy)methylcy-
tosine and its oxidized derivatives, Cell 152 (2013)
1146e1159, https://doi.org/10.1016/j.cell.2013.02.004.
[152] H.T. Yan, T. Shinka, K. Kinoshita, Y. Sato, M. Umeno,
G. Chen, K. Tsuji, Y. Unemi, X.J. Yang, T. Iwamoto,
Y. Nakahori, Molecular analysis of TBL1Y, a Y-linked
homologue of TBL1X related with X-linked late-onset
1622 MeCP2 function in Brainsensorineural deafness, J. Hum. Genet. 50 (2005)
175e181, https://doi.org/10.1007/s10038-005-0237-9.
[153] M. Zaghlula, D.G. Glaze, G.M. Enns, L. Potocki,
A.L. Schwabe, B. Suter, Current clinical evidence does
not support a link between TBL1XR1 and Rett syndrome:
description of one patient with Rett features and a novel
mutation in TBL1XR1, and a review of TBL1XR1 pheno-
types, Am. J. Med. Genet. Part A. 176 (2018) 1683e1687,
https://doi.org/10.1002/ajmg.a.38689.
[154] C.A. Heinen, A. Jongejan, P.J. Watson, B. Redeker,
A. Boelen, O. Boudzovitch-Surovtseva, F. Forzano,
R. Hordijk, R. Kelley, A.H. Olney, M.E. Pierpont,
G.B. Schaefer, F. Stewart, a S.P. van Trotsenburg,
E. Fliers, J.W.R. Schwabe, R.C. Hennekam, A specific
mutation in TBL1XR1 causes Pierpont syndrome, J. Med.
Genet. 53 (2016) 330e337, https://doi.org/10.1136/jmed-
genet-2015-103233.
[155] G. Bracaglia, B. Conca, A. Bergo, L. Rusconi, Z. Zhou,
M.E. Greenberg, N. Landsberger, S. Soddu, C. Kilstrup-
Nielsen, Methyl-CpG-binding protein 2 is phosphorylated
by homeodomain-interacting protein kinase 2 and con-
tributes to apoptosis, EMBO Rep. 10 (2009) 1327e1333,
https://doi.org/10.1038/embor.2009.217.
[156] R.Y. Tweedie-Cullen, J.M. Reck, I.M. Mansuy, Compre-
hensive mapping of post-translational modifications on
synaptic, nuclear, and histone proteins in the adult mouse
brain, J. Proteome Res. 8 (2009) 4966e4982, https://
doi.org/10.1021/pr9003739.
[157] E.L. Huttlin, M.P. Jedrychowski, J.E. Elias, T. Goswami,
R. Rad, S.A. Beausoleil, J. Villen, W. Haas, M.E. Sowa,
S.P. Gygi, A tissue-specific atlas of mouse protein
phosphorylation and expression, Cell 143 (2010)
1174e1189, https://doi.org/10.1016/j.cell.2010.12.001.
[158] M.L. Gonzales, S. Adams, K.W. Dunaway, J.M. LaSalle,
Phosphorylation of distinct sites in MeCP2 modifies
cofactor associations and the dynamics of transcriptional
regulation, Mol. Cell. Biol. 32 (2012) 2894e2903, https://
doi.org/10.1128/MCB.06728-11.
[159] D.H. Yasui, M.L. Gonzales, J.O. Aflatooni, F.K. Crary,
D.J. Hu, B.J. Gavino, M.S. Golub, J.B. Vincent,
N.C. Schanen, C.O. Olson, M. Rastegar, J.M. Lasalle,
Mice with an isoform-ablating Mecp2exon 1 mutation
recapitulate the neurologic deficits of Rett syndrome,
Hum. Mol. Genet. 23 (2014) 2447e2458, https://doi.org/
10.1093/hmg/ddt640.
[160] A. Bergo, M. Strollo, M. Gai, I. Barbiero, G. Stefanelli,
S. Sertic, C.C. Gigli, F. Di Cunto, C. Kilstrup-Nielsen,
N. Landsberger, Methyl-CpG binding protein 2 (MeCP2)
localizes at the centrosome and is required for proper
mitotic spindle organization, J. Biol. Chem. 290 (2015)
3223e3237, https://doi.org/10.1074/jbc.M114.608125.
[161] J. Cheng, M. Huang, Y. Zhu, Y.J. Xin, Y.K. Zhao, J. Huang,
J.X. Yu, W.H. Zhou, Z. Qiu, SUMOylation of MeCP2 is
essential for transcriptional repression and hippocampal
synapse development, J. Neurochem. 128 (2014)
798e806, https://doi.org/10.1111/jnc.12523.
[162] D.J.C. Tai, Y.C. Liu, W.L. Hsu, Y.L. Ma, S.J. Cheng,
S.Y. Liu, E.H.Y. Lee, MeCP2 SUMOylation rescues
Mecp2-mutant-induced behavioural deficits in a mouse
model of Rett syndrome, Nat. Commun. 7 (2016) 10552,
https://doi.org/10.1038/ncomms10552.
[163] L. Zocchi, P. Sassone-Corsi, SIRT1-mediated deacetyla-
tion of MeCP2 contributes to BDNF expression, Epige-netics 7 (2012) 695e700, https://doi.org/10.4161/
epi.20733.
[164] A. Guo, H. Gu, J. Zhou, D. Mulhern, Y. Wang, K.A. Lee,
V. Yang, M. Aguiar, J. Kornhauser, X. Jia, J. Ren,
S.A. Beausoleil, J.C. Silva, V. Vemulapalli, M.T. Bedford,
M.J. Comb, Immunoaffinity enrichment and mass spectro-
metry analysis of protein methylation, Technol. Innov.
Resour. 13 (2014) 372e387, https://doi.org/10.1074/
mcp.O113.027870.
[165] Z. Wang, N.D. Udeshi, M.O. Malley, J. Shabanowitz,
D.F. Hunt, G.W. Hart, Enrichment and site mapping of O-
linked N-acetylglucosamine by a combination of chemical/
enzymatic tagging, photochemical cleavage, and electron
transfer dissociation mass spectrometry, Mol. Cell. Pro-
teom. 9 (2010) 153e160, https://doi.org/10.1074/
mcp.M900268-MCP200.
[166] A. Becker, P. Zhang, L. Allmann, D. Meilinger, B. Bertulat,
D. Eck, M. Hofstaetter, G. Bartolomei, M. Hottiger,
V. Schreiber, H. Leonhardt, M.C. Cardoso, Poly(ADP-
ribosyl)ation of methyl CpG binding domain protein 2
regulates chromatin structure, J. Biol. Chem. 291 (2016)
4873e4881, https://doi.org/10.1074/jbc.M115.698357.
[167] K.D. Kernohan, Y. Jiang, D.C. Tremblay, A.C. Bonvissuto,
J.H. Eubanks, M.R.W. Mann, N.G. Berube, ATRX partners
with cohesin and MeCP2 and contributes to developmental
silencing of imprinted genes in the brain, Dev. Cell 18
(2010) 191e202, ht tps: / /do i .org/10.1016/ j .dev-
cel.2009.12.017.
[168] A. Guarda, F. Bolognese, I.M. Bonapace, G. Badaracco,
Interaction between the inner nuclear membrane lamin B
receptor and the heterochromatic methyl binding protein,
MeCP2, Exp. Cell Res. 315 (2009) 1895e1903, https://
doi.org/10.1016/j.yexcr.2009.01.019.
[169] H. Kimura, K. Shiota, Methyl-CpG-binding protein, MeCP2,
is a target molecule for maintenance DNA methyltransfer-
ase, Dnmt1. J. Biol. Chem. 278 (2003) 4806e4812, https://
doi.org/10.1074/jbc.M209923200.
[170] P.-F. Cartron, A. Nadaradjane, F. Lepape, L. Lalier,
B. Gardie, F.M. Vallette, Identification of TET1 partners
that control its DNA-demethylating function, Genes Cancer
4 ( 2013 ) 235e241 , h t t p s : / / do i . o r g / 1 0 . 1177 /
1947601913489020.
[171] D.M. Murphy, P.G. Buckley, S. Das, K.M. Watters,
K. Bryan, R.L. Stallings, Co-localization of the oncogenic
transcription factor MYCN and the DNA methyl binding
protein MeCP2 at genomic sites in neuroblastoma, PLoS
One 6 (2011), e21436, https://doi.org/10.1371/journal.-
pone.0021436.
[172] S.W. Long, J.Y. Ooi, P.M. Yau, P.L. Jones, A brain-derived
MeCP2 complex supports a role for MeCP2 in RNA
processing, Biosci. Rep. 31 (2011) 333e343, https://
doi.org/10.1042/BSR20100124.
[173] R. Li, Q. Dong, X. Yuan, X. Zeng, Y. Gao, C. Chiao, H. Li,
X. Zhao, S. Keles, Z. Wang, Q. Chang, Misregulation of
alternative splicing in a mouse model of Rett syndrome,
PLoS Genet. 12 (2016), e1006129, https://doi.org/10.1371/
journal.pgen.1006129.
[174] S.G. Dastidar, F.H. Bardai, C. Ma, V. Price, V. Rawat,
P. Verma, V. Narayanan, S.R. D'Mello, Isoform-specific
toxicity of Mecp2 in postmitotic neurons: suppression of
neurotoxicity by FoxG1, J. Neurosci. 32 (2012)
2846e2855, https://doi.org/10.1523/JNEUROSCI.5841-
11.2012.
1623MeCP2 function in Brain[175] F. Mari, S. Azimonti, I. Bertani, F. Bolognese, E. Colombo,
R. Caselli, E. Scala, I. Longo, S. Grosso, C. Pescucci,
F. Ariani, G. Hayek, P. Balestri, A. Bergo, G. Badaracco,
M. Zappella, V. Broccoli, A. Renieri, C. Kilstrup-Nielsen,
N. Landsberger, CDKL5 belongs to the same molecular
pathway of MeCP2 and it is responsible for the early-onset
seizure variant of Rett syndrome, Hum. Mol. Genet. 14
(2005) 1935e1946, https://doi.org/10.1093/hmg/ddi198.
[176] A. Khoshnan, P.H. Patterson, Elevated IKKalpha accel-
erates the differentiation of human neuronal progenitor
cells and induces MeCP2-dependent BDNF expression,
PLoS One 7 (2012), e41794, https://doi.org/10.1371/
journal.pone.0041794.
[177] K.N. McFarland, M.N. Huizenga, S.B. Darnell,
G.R. Sangrey, O. Berezovska, J.H.J. Cha, T.F. Outeiro,
G. Sadri-Vakili, MeCP2: a novel huntingtin interactor,
Hum. Mol. Genet. 23 (2014) 1036e1044, https://doi.org/
10.1093/hmg/ddt499.
[178] A. Becker, L. Allmann, M. Hofst€atter, V. Casa, P. Weber,
A. Lehmkuhl, H.D. Herce, M.C. Cardoso, Direct homo- and
hetero-interactions of MeCP2 and MBD2, PLoS One 8
(2013), e53730, https://doi.org/10.1371/journal.-
pone.0053730.
[179] Q. Chang, G. Khare, V. Dani, S. Nelson, R. Jaenisch, The
disease progression of Mecp2 mutant mice is affected by
the level of BDNF expression, Neuron 49 (2006) 341e348,
https://doi.org/10.1016/j.neuron.2005.12.027.
[180] G.J. Pelka, C.M. Watson, T. Radziewic, M. Hayward,
H. Lahooti, J. Christodoulou, P.P.L. Tam, Mecp2 deficiency
is associated with learning and cognitive deficits and
altered gene activity in the hippocampal region of mice,
Brain 129 (2006) 887e898, https://doi.org/10.1093/brain/
awl022.
[181] L.L.L. Orefice, A.L.L. Zimmerman, A.M.M. Chirila,
S.J.J. Sleboda, J.P.P. Head, D.D.D. Ginty, Peripheral
mechanosensory neuron dysfunction underlies tactile and
behavioral deficits in mouse models of ASDs, Cell 166
( 2 0 1 6 ) 2 9 9e3 1 3 , h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 /
j.cell.2016.05.033.
[182] A. Lawson-Yuen, D. Liu, L. Han, Z.I. Jiang, G.E. Tsai,
A.C. Basu, J. Picker, J. Feng, J.T. Coyle, Ube3a mRNA
and protein expression are not decreased in Mecp2R168X
mutant mice, Brain Res. 1180 (2007) 1e6, https://doi.org/
10.1016/j.brainres.2007.08.039.
[183] L.R. Schaevitz, N.B. Gomez, D.P. Zhen, J.E. Berger-
Sweeney, MeCP2 R168X male and female mutant mice
exhibit Rett-like behavioral deficits, Genes Brain Behav. 12
(2013) 732e740, https://doi.org/10.1111/gbb.12070.
[184] E. Wegener, C. Brendel, A. Fischer, S. Hülsmann,
J. G€artner, P. Huppke, Characterization of the
MeCP2R168X knockin mouse model for Rett syndrome,
PLoS One 9 (2014), e115444, https://doi.org/10.1371/
journal.pone.0115444.
[185] M.R. Pitcher, J.A. Herrera, S.A. Buffington, M.Y. Kochukov,
J.K. Merritt, A.R. Fisher, N.C. Schanen, M. Costa-Mattioli,
J.L. Neul, Rett syndrome like phenotypes in the R255X
Mecp2 mutant mouse are rescued by MECP2 transgene,
Hum. Mol. Genet. 24 (2015) 2662e2672, https://doi.org/
10.1093/hmg/ddv030.
[186] C.S. Casas-Delucchi, A. Becker, J.J. Bolius, M. Cristina
Cardoso, Targeted manipulation of heterochromatin res-cues MeCP2 Rett mutants and re-establishes higher order
chromatin organization, Nucleic Acids Res. 40 (2012),
https://doi.org/10.1093/nar/gks784.
[187] E. Ballestar, T.M. Yusufzai, A.P. Wolffe, Effects of Rett
syndrome mutations of the Methyl-CpG binding domain of
the transcriptional repressor MeCP2 on selectivity for
association with methylated DNA, Biochemistry 39 (2000)
7100e7106, https://doi.org/10.1021/bi0001271.
[188] T.M. Yusufzai, A.P. Wolffe, Functional consequences of
Rett syndrome mutations on human MeCP2, Nucleic Acids
Res. 28 (2000) 4172e4179, https://doi.org/10.1093/nar/
28.21.4172.
[189] A. Free, R.I.D. Wakefield, B.O. Smith, D.T.F. Drydenll,
P.N. Barlow, A.P. Bird, DNA recognition by the methyl-CpG
binding domain of MeCP2, J. Biol. Chem. 276 (2001)
3353e3360, https://doi.org/10.1074/jbc.M007224200.
[190] S. Kudo, M. Tamura, Y. Nomura, M. Segawa, N. Fujita,
M. Nakao, J. Dragich, C. Schanen, Functional analyses of
MeCP2 mutations associated with Rett syndrome using
transient expression systems, Brain Dev. 23 (2001)
165e173, https://doi.org/10.1016/S0387-7604(01)00345-
X.
[191] T. Baubec, R. Ivanek, F. Lienert, D. Schübeler, Methyla-
tion-dependent and -independent genomic targeting prin-
ciples of the MBD protein family, Cell 153 (2013) 480e492,
https://doi.org/10.1016/j.cell.2013.03.011.
[192] J.R. Sinnamon, S.Y. Kim, G.M. Corson, Z. Song, H. Nakai,
J.P. Adelman, G. Mandel, Site-directed RNA repair of
endogenous Mecp2 RNA in neurons, Proc. Natl. Acad. Sci.
U. S. A. 114 (2017) E9395eE9402, https://doi.org/10.1073/
pnas.1715320114.
[193] I. D'Annessa, A. Gandaglia, E. Brivio, G. Stefanelli,
A. Frasca, N. Landsberger, D. Di Marino, Tyr120Asp
mutation alters domain flexibility and dynamics of MeCP2
DNA binding domain leading to impaired DNA interaction:
atomistic characterization of a Rett syndrome causing
mutation, Biochim. Biophys. Acta Gen. Subj. 1862 (2018)
1180e1189, https://doi.org/10.1016/j.bbagen.2018.02.005.
[194] R.P. Ghosh, R.A. Horowitz-Scherer, T. Nikitina,
L.M. Gierasch, C.L. Woodcock, Rett syndrome-causing
mutations in human MeCP2 result in diverse structural
changes that impact folding and DNA interactions, J. Biol.
Chem. 283 (2008) 20523e20534, https://doi.org/10.1074/
jbc.M803021200.
[195] B.J.O. Roak, L. Vives, W. Fu, J.D. Egertson, I.B. Stanaway,
G. Ian, G. Carvill, A. Kumar, C. Lee, K. Ankenman,
J. Munson, J.B. Hiatt, E.H. Turner, R. Levy, D.R.O. Day,
N. Krumm, P. Bradley, B.K. Martin, E. Borenstein, D. a
Nickerson, C. Heather, D. Doherty, J.M. Akey, R. Bernier,
E.E. Eichler, J. Shendure, Multiplex targeted sequencing
identifies recurrently mutated genes in autism spectrum
disorders, Science 338 (2012) 1619e1622, https://doi.org/
10.1126/science.1227764.
[196] B.J.O. Roak, L. Vives, S. Girirajan, E. Karakoc, N. Krumm,
P. Coe, R. Levy, A. Ko, C. Lee, J.D. Smith, E.H. Turner,
B. Ian, B. Vernot, M. Malig, C. Baker, B. Reilly, J.M. Akey,
E. Borenstein, M.J. Rieder, D. a Nickerson, R. Bernier,
E.E. Eichler, Sporadic autism exomes reveal a highly
interconnected protein network of de novo mutations,
Nature 485 (2012) 246e250, https://doi.org/10.1038/nat-
ure10989.
